Pediatric and Geriatric Pharmacology — MCQs

Q: What agent is used for pupil dilatation in children?

Atropine. **Explanation:** In pediatric ophthalmology, the drug of choice for pupil dilatation and cycloplegic refraction is **Atropine**. **1. Why Atropine is Correct:** Children have very high accommodative power due to a strong ciliary muscle. To perform an accurate refraction (especially to detect latent hypermetropia or accommodative esotropia), complete paralysis of the ciliary muscle (**cycloplegia**) is required. Atropine is the most potent cycloplegic available. It is typically administered as a 1% ointment or drops for 3 days prior to the examination to ensure maximal effect. **2. Why the other options are incorrect:** * **Homatropine:** It is a semi-synthetic derivative of atropine but is significantly less potent. It is rarely used for refraction in children because it may result in incomplete cycloplegia. * **Tropicamide:** While it has the fastest onset and shortest duration (making it the drug of choice for adults), its cycloplegic action is too weak for the strong accommodative reflex of a child. * **Phenylephrine:** This is a sympathomimetic (alpha-1 agonist) that causes mydriasis (dilation) but **no cycloplegia**. It is often used as an adjunct but cannot be used alone for pediatric refraction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Atropine is the DOC for children <7 years; Cyclopentolate is preferred for children 7–12 years; Tropicamide is preferred for adults. * **Systemic Toxicity:** In children, always apply pressure over the lacrimal sac (punctal occlusion) after instilling drops to prevent systemic absorption, which can cause "Atropine flushing," fever, and tachycardia. * **Contraindication:** Avoid atropine in children with Down Syndrome, as they may show an exaggerated pupillary response and heart rate.

Q: Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?

Folic acid. **Explanation:** **Phenytoin** is a widely used antiepileptic drug known for its specific metabolic side effects, particularly regarding folate metabolism. **Why Folic Acid is the Correct Answer:** Phenytoin causes folic acid deficiency through three primary mechanisms: 1. **Inhibition of Absorption:** It inhibits the enzyme intestinal conjugase, which is required to break down dietary polyglutamates into absorbable monoglutamates. 2. **Enzyme Induction:** As a potent inducer of hepatic CYP450 enzymes, phenytoin increases the demand for folate as a co-factor in drug metabolism. 3. **Antagonism:** It may interfere with the uptake of folate by cells. In pregnant women, this deficiency is critical as it significantly increases the risk of **Neural Tube Defects (NTDs)** and can lead to megaloblastic anemia. **Why Other Options are Incorrect:** * **Vitamin B6 (Pyridoxine):** Deficiency is classically associated with **Isoniazid (INH)** therapy, not phenytoin. * **Vitamin B12:** While B12 deficiency also causes megaloblastic anemia, phenytoin specifically targets folate pathways. B12 deficiency is more common in metformin use or gastric bypass. * **Vitamin A:** Phenytoin does not interfere with the absorption or metabolism of fat-soluble Vitamin A. **High-Yield Clinical Pearls for NEET-PG:** * **Fetal Hydantoin Syndrome:** Characterized by craniofacial anomalies (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. * **Vitamin K Deficiency:** Phenytoin can also cause a deficiency of Vitamin K in the newborn, leading to coagulation defects. Prophylactic Vitamin K is often given to the mother in the last month of pregnancy. * **Management:** Pregnant women on phenytoin should receive high-dose folic acid (5 mg/day) to mitigate the risk of NTDs.

Q: Which of the following medications is absolutely contraindicated for a mother who is breastfeeding her newborn baby?

Amphetamines. **Explanation:** The safety of medications during breastfeeding depends on the drug's concentration in breast milk, its oral bioavailability in the infant, and its potential for toxicity. **1. Why Amphetamines are the Correct Answer:** Amphetamines (Option A) are **absolutely contraindicated** during breastfeeding. They are highly lipophilic and concentrate in breast milk at levels much higher than maternal plasma. In newborns, they can cause significant CNS stimulation, leading to irritability, agitation, poor sleeping patterns, tachycardia, and potential long-term neurodevelopmental issues. Furthermore, amphetamines can suppress maternal prolactin levels, potentially interfering with milk production. **2. Analysis of Incorrect Options:** * **Carbamazepine (Option B):** Considered "compatible" with breastfeeding by the AAP. While it does enter breast milk, the amounts are usually sub-clinical. Monitoring for infant jaundice or sedation is advised, but it is not a contraindication. * **Labetalol (Option C):** This is a preferred beta-blocker in lactation because it is highly protein-bound, resulting in very low concentrations in breast milk. * **Ibuprofen (Option D):** The NSAID of choice for breastfeeding mothers. It has extremely low excretion into milk and a short half-life, making it safe for the infant. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications to Breastfeeding (Maternal Drugs):** Anticancer drugs (antimetabolites), Radioactive isotopes (e.g., Iodine-131), Lithium, Ergotamine, Retinoids, and Drugs of abuse (Cocaine, Amphetamines). * **Safe Alternatives:** If a mother needs an antibiotic, **Penicillins/Cephalosporins** are preferred over Tetracyclines. For analgesia, **Paracetamol/Ibuprofen** are preferred over Aspirin (due to Reye’s syndrome risk). * **Rule of Thumb:** Drugs with high molecular weight, high protein binding, and low lipid solubility are less likely to cross into breast milk.

Q: Which parameter is most important for determining drug dosage in a child?

Weight. **Explanation:** **1. Why Weight is the Correct Answer:** In pediatric pharmacology, **Body Weight (kg)** is the most widely used and practical parameter for calculating drug dosages. This is because children undergo rapid physiological changes, and weight serves as a reliable proxy for the volume of distribution ($V_d$) and metabolic capacity. Most pediatric drug references (like the IPV or Nelson’s) provide dosages in **mg/kg/day**. While Body Surface Area (BSA) is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), weight remains the standard bedside parameter for general prescribing. **2. Why Other Options are Incorrect:** * **Age (B):** Age-based formulas (e.g., Young’s or Dilling’s rule) are largely obsolete. Age does not account for the significant variation in growth; two 5-year-olds can have vastly different weights, leading to potential under-dosing or toxicity. * **Height (C):** Height alone does not correlate well with the metabolic rate or the volume of distribution of most drugs. It is primarily used to calculate BSA or to assess growth milestones. * **Investigation Results (D):** While renal (creatinine) or hepatic function tests are crucial for *adjusting* doses in sick children, they are not the primary parameter for *determining* the initial baseline dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **BSA Calculation:** The most accurate method for pediatric dosing is **Body Surface Area (BSA)**, calculated using the Mosteller formula: $\sqrt{\frac{Height(cm) \times Weight(kg)}{3600}}$. * **Clark’s Rule:** A classic (though less used) formula based on weight: $\text{Child Dose} = \frac{\text{Weight in lbs}}{150} \times \text{Adult Dose}$. * **Neonatal Caution:** In neonates, weight-based dosing must be adjusted for their higher total body water percentage and immature glucuronidation (e.g., risk of Gray Baby Syndrome with Chloramphenicol).

Q: The most common adverse effect particularly seen in young children because of the use of sodium valproate is:

Hepatitis. **Explanation:** **Sodium Valproate** is a broad-spectrum antiepileptic drug, but its use in the pediatric population requires extreme caution due to the risk of **idiosyncratic hepatotoxicity** [1], [2]. 1. **Why Hepatitis is Correct:** The most serious and potentially fatal adverse effect of valproate is **fulminant hepatitis (Hepatotoxicity)**. This risk is significantly higher in children **under the age of 2 years**, especially those on polytherapy or those with underlying metabolic/mitochondrial disorders (e.g., POLG mutations). The mechanism involves the formation of toxic metabolites like 4-pentenoic acid, which interfere with mitochondrial fatty acid oxidation. 2. **Analysis of Incorrect Options:** * **Loss of hair (Alopecia):** This is a common side effect of valproate (often resulting in curly hair regrowth), but it is not life-threatening and is seen across all age groups, not specifically "particularly" concerning in young children compared to hepatitis. * **Anorexia:** While gastrointestinal upset is common, valproate more frequently causes **increased appetite and weight gain** rather than anorexia. * **Tremor:** This is a dose-related side effect typically seen in older children and adults on long-term therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Valproate is highly teratogenic, causing **Neural Tube Defects** (Spina Bifida) by interfering with folate metabolism. * **Pancreatitis:** It is a known cause of acute hemorrhagic pancreatitis. * **Monitoring:** LFTs (Liver Function Tests) should be performed before and during the first 6 months of therapy. * **Other Side Effects (Mnemonic: VALPROATE):** **V**omiting, **A**lopecia, **L**iver toxicity, **P**ancreatitis/Platelets low, **R**etention of fat (Weight gain), **O**edema, **A**norexia (rarely), **T**remor/Teratogenicity, **E**ncephalopathy (Hyperammonemia).

Q: Gray baby syndrome is caused by which of the following drugs?

Chloramphenicol. **Explanation:** **Gray Baby Syndrome** is a serious and potentially fatal adverse reaction associated with the administration of **Chloramphenicol** in neonates (especially premature infants). **Why Chloramphenicol is the correct answer:** The syndrome occurs due to the physiological immaturity of the neonatal liver and kidneys. There are two primary mechanisms: 1. **Deficiency of Glucuronyl Transferase:** Neonates lack sufficient levels of this enzyme, which is required to conjugate chloramphenicol into its inactive form. 2. **Reduced Renal Excretion:** Immature kidneys cannot effectively excrete the unconjugated drug. This leads to toxic accumulation of the drug, causing mitochondrial injury. Clinical features include abdominal distension, vomiting, progressive cyanosis (giving the skin a characteristic **ash-gray color**), hypothermia, and cardiovascular collapse. **Why other options are incorrect:** * **Chlorpromazine:** An antipsychotic that can cause extrapyramidal symptoms or neonatal withdrawal if used during pregnancy, but not Gray Baby Syndrome. * **Phenytoin:** An antiepileptic known for **Fetal Hydantoin Syndrome** (cleft lip/palate, microcephaly) if taken during pregnancy, and gingival hyperplasia in children. * **Gentamycin:** An aminoglycoside primarily associated with **ototoxicity and nephrotoxicity** in all age groups. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment:** Immediate discontinuation of the drug; exchange transfusion or charcoal hemoperfusion may be required. * **Other Chloramphenicol Side Effects:** Dose-dependent bone marrow suppression and idiosyncratic **Aplastic Anemia** (most serious). * **Drug of Choice:** Chloramphenicol remains a backup for Typhoid fever and H. influenzae meningitis in specific settings, but its use is strictly limited in neonates.

Q: Which drug can cause hypertrophic pyloric stenosis?

Erythromycin. **Explanation:** **Erythromycin** is the correct answer. The association between macrolide antibiotics and **Infantile Hypertrophic Pyloric Stenosis (IHPS)** is a well-documented clinical phenomenon. **Mechanism:** Erythromycin acts as a **motilin receptor agonist**. Motilin is a hormone that stimulates gastrointestinal motility. In neonates, particularly those under 2 weeks of age, exposure to erythromycin (either directly or through breast milk) triggers intense, non-coordinated contractions of the pyloric antrum. This repetitive mechanical stress leads to muscular hypertrophy of the pylorus, resulting in gastric outlet obstruction. **Analysis of Options:** * **B. Erythromycin:** This is the most strongly associated drug. The risk is highest when administered in the first two weeks of life for conditions like pertussis prophylaxis or ophthalmia neonatorum. * **C. Azithromycin:** While some studies suggest a potential risk with azithromycin, the association is significantly weaker and less clinically established than with erythromycin. * **A. Rifampicin & D. Ampicillin:** These drugs are not associated with pyloric hypertrophy. Rifampicin is known for causing orange-colored secretions, and Ampicillin is a common cause of antibiotic-associated diarrhea or rashes. **NEET-PG High-Yield Pearls:** * **Clinical Presentation:** IHPS typically presents at 3–6 weeks of age with **non-bilious, projectile vomiting** and a palpable "olive-shaped" mass in the epigastrium. * **Metabolic Profile:** It causes **Hypochloremic, Hypokalemic Metabolic Alkalosis** (due to loss of HCl from the stomach). * **Drug of Choice for Pertussis:** Despite the risk of IHPS, macrolides remain the treatment of choice for Pertussis, but infants must be monitored closely for symptoms of vomiting.

Pediatric and Geriatric Pharmacology — MCQs

Pediatric and Geriatric Pharmacology Indian Medical PG Practice Questions and MCQs

Question 1: What is the effect of indomethacin on the ductus arteriosus?

A. Closure of the ductus in premature neonates (Correct Answer)
B. Patent ductus arteriosus
C. Closure of the ductus in term and premature neonates
D. Closure of the ductus in older children

Explanation: **Explanation:** **Mechanism of Action:** The patency of the ductus arteriosus (DA) in utero is maintained by high levels of circulating **Prostaglandin E2 (PGE2)**, which acts as a potent vasodilator. **Indomethacin** is a non-selective Cyclooxygenase (COX) inhibitor. By inhibiting the COX enzyme, it decreases the synthesis of PGE2, leading to the constriction and subsequent functional **closure of the ductus arteriosus.** **Why Option A is Correct:** Indomethacin is specifically effective in **premature neonates** because their ductal tissue is highly sensitive to prostaglandin levels. In these infants, the ductus often fails to close spontaneously due to hypoxia or immature lungs, and pharmacological intervention can prevent the need for surgical ligation. **Analysis of Incorrect Options:** * **Option B:** This describes the pathology itself. Indomethacin is the *treatment* for Patent Ductus Arteriosus (PDA), not the cause. * **Option C:** Indomethacin is generally **ineffective in term neonates**. In full-term infants, the ductal smooth muscle is more developed and less dependent on prostaglandins for patency; closure is primarily driven by the postnatal rise in oxygen tension. * **Option D:** In older children, the ductus has typically undergone anatomical remodeling (fibrosis into the ligamentum arteriosum) or is too structurally fixed for prostaglandin inhibition to have any effect. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen (IV)** is now often preferred due to a lower risk of renal toxicity and necrotizing enterocolitis (NEC). * **Alternative:** **Paracetamol (Acetaminophen)** is an emerging alternative for PDA closure with a superior safety profile. * **Opposite Effect:** If a neonate has a cyanotic heart defect (e.g., Transposition of Great Arteries), we want to keep the ductus open. The drug used for this is **Alprostadil (PGE1 analog)**.

Question 2: Dosage of a drug in a child is typically calculated based on which of the following parameters?

A. Race
B. Weight (Correct Answer)
C. Sex
D. Height

Explanation: **Explanation:** In pediatric pharmacology, drug dosing is not a "one size fits all" approach because children are not merely "small adults." Their physiological processes—including gastric emptying, total body water percentage, and organ maturation—differ significantly. **Why Weight is the Correct Answer:** Body weight (expressed in mg/kg) is the most common and practical parameter used for calculating pediatric dosages. It accounts for the significant variations in size across different pediatric age groups (neonates to adolescents). While **Body Surface Area (BSA)** is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), **weight-based dosing** remains the standard clinical gold standard for most routine medications due to its ease of calculation and reliability. **Why Other Options are Incorrect:** * **Race (A):** While pharmacogenomics can influence drug metabolism (e.g., Isoniazid acetylation), race is never used as a primary parameter for calculating initial pediatric dosages. * **Sex (C):** Hormonal differences between sexes generally do not impact drug dosing until puberty; it is not a standard parameter for pediatric calculations. * **Height (D):** Height alone does not account for body mass or metabolic capacity. It is, however, used as a component to calculate BSA. **High-Yield Clinical Pearls for NEET-PG:** * **Young’s Formula:** $Age / (Age + 12) \times \text{Adult Dose}$ (Used for children > 2 years). * **Dilling’s Formula:** $Age / 20 \times \text{Adult Dose}$ (Easier to calculate, often tested). * **Fried’s Formula:** $Age (\text{in months}) / 150 \times \text{Adult Dose}$ (Used specifically for infants). * **Clark’s Rule:** $Weight (\text{in lbs}) / 150 \times \text{Adult Dose}$ (Based on weight). * **Gold Standard:** BSA-based dosing is superior to weight-based dosing for precision but is more complex to calculate ($BSA = \sqrt{[Height(cm) \times Weight(kg)] / 3600}$).

Question 3: What agent is used for pupil dilatation in children?

A. Atropine (Correct Answer)
B. Homatropine
C. Tropicamide
D. Phenylephrine

Explanation: **Explanation:** In pediatric ophthalmology, the drug of choice for pupil dilatation and cycloplegic refraction is **Atropine**. **1. Why Atropine is Correct:** Children have very high accommodative power due to a strong ciliary muscle. To perform an accurate refraction (especially to detect latent hypermetropia or accommodative esotropia), complete paralysis of the ciliary muscle (**cycloplegia**) is required. Atropine is the most potent cycloplegic available. It is typically administered as a 1% ointment or drops for 3 days prior to the examination to ensure maximal effect. **2. Why the other options are incorrect:** * **Homatropine:** It is a semi-synthetic derivative of atropine but is significantly less potent. It is rarely used for refraction in children because it may result in incomplete cycloplegia. * **Tropicamide:** While it has the fastest onset and shortest duration (making it the drug of choice for adults), its cycloplegic action is too weak for the strong accommodative reflex of a child. * **Phenylephrine:** This is a sympathomimetic (alpha-1 agonist) that causes mydriasis (dilation) but **no cycloplegia**. It is often used as an adjunct but cannot be used alone for pediatric refraction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Atropine is the DOC for children <7 years; Cyclopentolate is preferred for children 7–12 years; Tropicamide is preferred for adults. * **Systemic Toxicity:** In children, always apply pressure over the lacrimal sac (punctal occlusion) after instilling drops to prevent systemic absorption, which can cause "Atropine flushing," fever, and tachycardia. * **Contraindication:** Avoid atropine in children with Down Syndrome, as they may show an exaggerated pupillary response and heart rate.

Question 4: Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?

A. Vitamin B6
B. Vitamin B12
C. Vitamin A
D. Folic acid (Correct Answer)

Explanation: **Explanation:** **Phenytoin** is a widely used antiepileptic drug known for its specific metabolic side effects, particularly regarding folate metabolism. **Why Folic Acid is the Correct Answer:** Phenytoin causes folic acid deficiency through three primary mechanisms: 1. **Inhibition of Absorption:** It inhibits the enzyme intestinal conjugase, which is required to break down dietary polyglutamates into absorbable monoglutamates. 2. **Enzyme Induction:** As a potent inducer of hepatic CYP450 enzymes, phenytoin increases the demand for folate as a co-factor in drug metabolism. 3. **Antagonism:** It may interfere with the uptake of folate by cells. In pregnant women, this deficiency is critical as it significantly increases the risk of **Neural Tube Defects (NTDs)** and can lead to megaloblastic anemia. **Why Other Options are Incorrect:** * **Vitamin B6 (Pyridoxine):** Deficiency is classically associated with **Isoniazid (INH)** therapy, not phenytoin. * **Vitamin B12:** While B12 deficiency also causes megaloblastic anemia, phenytoin specifically targets folate pathways. B12 deficiency is more common in metformin use or gastric bypass. * **Vitamin A:** Phenytoin does not interfere with the absorption or metabolism of fat-soluble Vitamin A. **High-Yield Clinical Pearls for NEET-PG:** * **Fetal Hydantoin Syndrome:** Characterized by craniofacial anomalies (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. * **Vitamin K Deficiency:** Phenytoin can also cause a deficiency of Vitamin K in the newborn, leading to coagulation defects. Prophylactic Vitamin K is often given to the mother in the last month of pregnancy. * **Management:** Pregnant women on phenytoin should receive high-dose folic acid (5 mg/day) to mitigate the risk of NTDs.

Question 5: Which of the following drugs are known to cause fetal renal anomalies?

A. Frusemide
B. Enalapril (Correct Answer)
C. Angiotensin receptor blocker
D. Amlodipine

Explanation: **Explanation:** The correct answer is **Enalapril** (and by extension, Angiotensin Receptor Blockers, though Enalapril is the classic prototype cited in this context). **1. Why Enalapril is Correct:** Enalapril is an **ACE Inhibitor (ACEI)**. ACEIs are strictly contraindicated in the 2nd and 3rd trimesters of pregnancy because they interfere with the fetal Renin-Angiotensin-Aldosterone System (RAAS). Fetal renal perfusion and development are highly dependent on Angiotensin II. Inhibition leads to **fetal renal dysgenesis**, which results in **oligohydramnios** (decreased amniotic fluid). This lack of fluid causes the "Oligohydramnios Sequence" (Potter’s sequence), characterized by pulmonary hypoplasia, limb contractures, and cranial ossification defects. **2. Analysis of Other Options:** * **Angiotensin Receptor Blockers (ARBs):** While ARBs also cause similar renal anomalies, **Enalapril** is the more frequently tested "classic" answer in NEET-PG for this specific complication. *Note: In many clinical scenarios, both B and C are considered fetotoxic; however, ACEIs have the longest-standing documented association with renal tubular dysgenesis.* * **Frusemide:** This is a loop diuretic. While generally avoided in pregnancy due to the risk of decreased placental perfusion, it is not a primary teratogen associated with structural renal anomalies. * **Amlodipine:** This is a Calcium Channel Blocker (CCB). CCBs are generally considered safe or have no proven teratogenic risk in humans; Nifedipine is actually frequently used to manage gestational hypertension. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Hypertension in Pregnancy:** Labetalol (followed by Methyldopa and Hydralazine). * **ACEI Teratogenicity:** Often referred to as **"ACEI Fetopathy."** * **Critical Window:** ACEIs are not typically structural teratogens in the *1st trimester* (though still avoided), but are lethal to the *fetal kidney* in the 2nd and 3rd trimesters. * **Key Triad:** Renal dysgenesis + Oligohydramnios + Hypocalvaria (skull defects).

Question 6: Which of the following medications is absolutely contraindicated for a mother who is breastfeeding her newborn baby?

A. Amphetamines (Correct Answer)
B. Carbamazepine
C. Labetalol
D. Ibuprofen

Explanation: **Explanation:** The safety of medications during breastfeeding depends on the drug's concentration in breast milk, its oral bioavailability in the infant, and its potential for toxicity. **1. Why Amphetamines are the Correct Answer:** Amphetamines (Option A) are **absolutely contraindicated** during breastfeeding. They are highly lipophilic and concentrate in breast milk at levels much higher than maternal plasma. In newborns, they can cause significant CNS stimulation, leading to irritability, agitation, poor sleeping patterns, tachycardia, and potential long-term neurodevelopmental issues. Furthermore, amphetamines can suppress maternal prolactin levels, potentially interfering with milk production. **2. Analysis of Incorrect Options:** * **Carbamazepine (Option B):** Considered "compatible" with breastfeeding by the AAP. While it does enter breast milk, the amounts are usually sub-clinical. Monitoring for infant jaundice or sedation is advised, but it is not a contraindication. * **Labetalol (Option C):** This is a preferred beta-blocker in lactation because it is highly protein-bound, resulting in very low concentrations in breast milk. * **Ibuprofen (Option D):** The NSAID of choice for breastfeeding mothers. It has extremely low excretion into milk and a short half-life, making it safe for the infant. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications to Breastfeeding (Maternal Drugs):** Anticancer drugs (antimetabolites), Radioactive isotopes (e.g., Iodine-131), Lithium, Ergotamine, Retinoids, and Drugs of abuse (Cocaine, Amphetamines). * **Safe Alternatives:** If a mother needs an antibiotic, **Penicillins/Cephalosporins** are preferred over Tetracyclines. For analgesia, **Paracetamol/Ibuprofen** are preferred over Aspirin (due to Reye’s syndrome risk). * **Rule of Thumb:** Drugs with high molecular weight, high protein binding, and low lipid solubility are less likely to cross into breast milk.

Question 7: Which parameter is most important for determining drug dosage in a child?

A. Weight (Correct Answer)
B. Age
C. Height
D. Investigation results

Explanation: **Explanation:** **1. Why Weight is the Correct Answer:** In pediatric pharmacology, **Body Weight (kg)** is the most widely used and practical parameter for calculating drug dosages. This is because children undergo rapid physiological changes, and weight serves as a reliable proxy for the volume of distribution ($V_d$) and metabolic capacity. Most pediatric drug references (like the IPV or Nelson’s) provide dosages in **mg/kg/day**. While Body Surface Area (BSA) is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), weight remains the standard bedside parameter for general prescribing. **2. Why Other Options are Incorrect:** * **Age (B):** Age-based formulas (e.g., Young’s or Dilling’s rule) are largely obsolete. Age does not account for the significant variation in growth; two 5-year-olds can have vastly different weights, leading to potential under-dosing or toxicity. * **Height (C):** Height alone does not correlate well with the metabolic rate or the volume of distribution of most drugs. It is primarily used to calculate BSA or to assess growth milestones. * **Investigation Results (D):** While renal (creatinine) or hepatic function tests are crucial for *adjusting* doses in sick children, they are not the primary parameter for *determining* the initial baseline dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **BSA Calculation:** The most accurate method for pediatric dosing is **Body Surface Area (BSA)**, calculated using the Mosteller formula: $\sqrt{\frac{Height(cm) \times Weight(kg)}{3600}}$. * **Clark’s Rule:** A classic (though less used) formula based on weight: $\text{Child Dose} = \frac{\text{Weight in lbs}}{150} \times \text{Adult Dose}$. * **Neonatal Caution:** In neonates, weight-based dosing must be adjusted for their higher total body water percentage and immature glucuronidation (e.g., risk of Gray Baby Syndrome with Chloramphenicol).

Question 8: The most common adverse effect particularly seen in young children because of the use of sodium valproate is:

A. Hepatitis (Correct Answer)
B. Loss of hair
C. Anorexia
D. Tremor

Explanation: **Explanation:** **Sodium Valproate** is a broad-spectrum antiepileptic drug, but its use in the pediatric population requires extreme caution due to the risk of **idiosyncratic hepatotoxicity** [1], [2]. 1. **Why Hepatitis is Correct:** The most serious and potentially fatal adverse effect of valproate is **fulminant hepatitis (Hepatotoxicity)**. This risk is significantly higher in children **under the age of 2 years**, especially those on polytherapy or those with underlying metabolic/mitochondrial disorders (e.g., POLG mutations). The mechanism involves the formation of toxic metabolites like 4-pentenoic acid, which interfere with mitochondrial fatty acid oxidation. 2. **Analysis of Incorrect Options:** * **Loss of hair (Alopecia):** This is a common side effect of valproate (often resulting in curly hair regrowth), but it is not life-threatening and is seen across all age groups, not specifically "particularly" concerning in young children compared to hepatitis. * **Anorexia:** While gastrointestinal upset is common, valproate more frequently causes **increased appetite and weight gain** rather than anorexia. * **Tremor:** This is a dose-related side effect typically seen in older children and adults on long-term therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Valproate is highly teratogenic, causing **Neural Tube Defects** (Spina Bifida) by interfering with folate metabolism. * **Pancreatitis:** It is a known cause of acute hemorrhagic pancreatitis. * **Monitoring:** LFTs (Liver Function Tests) should be performed before and during the first 6 months of therapy. * **Other Side Effects (Mnemonic: VALPROATE):** **V**omiting, **A**lopecia, **L**iver toxicity, **P**ancreatitis/Platelets low, **R**etention of fat (Weight gain), **O**edema, **A**norexia (rarely), **T**remor/Teratogenicity, **E**ncephalopathy (Hyperammonemia).

Question 9: Gray baby syndrome is caused by which of the following drugs?

A. Chlorpromazine
B. Chloramphenicol (Correct Answer)
C. Phenytoin
D. Gentamycin

Explanation: **Explanation:** **Gray Baby Syndrome** is a serious and potentially fatal adverse reaction associated with the administration of **Chloramphenicol** in neonates (especially premature infants). **Why Chloramphenicol is the correct answer:** The syndrome occurs due to the physiological immaturity of the neonatal liver and kidneys. There are two primary mechanisms: 1. **Deficiency of Glucuronyl Transferase:** Neonates lack sufficient levels of this enzyme, which is required to conjugate chloramphenicol into its inactive form. 2. **Reduced Renal Excretion:** Immature kidneys cannot effectively excrete the unconjugated drug. This leads to toxic accumulation of the drug, causing mitochondrial injury. Clinical features include abdominal distension, vomiting, progressive cyanosis (giving the skin a characteristic **ash-gray color**), hypothermia, and cardiovascular collapse. **Why other options are incorrect:** * **Chlorpromazine:** An antipsychotic that can cause extrapyramidal symptoms or neonatal withdrawal if used during pregnancy, but not Gray Baby Syndrome. * **Phenytoin:** An antiepileptic known for **Fetal Hydantoin Syndrome** (cleft lip/palate, microcephaly) if taken during pregnancy, and gingival hyperplasia in children. * **Gentamycin:** An aminoglycoside primarily associated with **ototoxicity and nephrotoxicity** in all age groups. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment:** Immediate discontinuation of the drug; exchange transfusion or charcoal hemoperfusion may be required. * **Other Chloramphenicol Side Effects:** Dose-dependent bone marrow suppression and idiosyncratic **Aplastic Anemia** (most serious). * **Drug of Choice:** Chloramphenicol remains a backup for Typhoid fever and H. influenzae meningitis in specific settings, but its use is strictly limited in neonates.

Question 10: Which drug can cause hypertrophic pyloric stenosis?

A. Rifampicin
B. Erythromycin (Correct Answer)
C. Azithromycin
D. Ampicillin

Explanation: **Explanation:** **Erythromycin** is the correct answer. The association between macrolide antibiotics and **Infantile Hypertrophic Pyloric Stenosis (IHPS)** is a well-documented clinical phenomenon. **Mechanism:** Erythromycin acts as a **motilin receptor agonist**. Motilin is a hormone that stimulates gastrointestinal motility. In neonates, particularly those under 2 weeks of age, exposure to erythromycin (either directly or through breast milk) triggers intense, non-coordinated contractions of the pyloric antrum. This repetitive mechanical stress leads to muscular hypertrophy of the pylorus, resulting in gastric outlet obstruction. **Analysis of Options:** * **B. Erythromycin:** This is the most strongly associated drug. The risk is highest when administered in the first two weeks of life for conditions like pertussis prophylaxis or ophthalmia neonatorum. * **C. Azithromycin:** While some studies suggest a potential risk with azithromycin, the association is significantly weaker and less clinically established than with erythromycin. * **A. Rifampicin & D. Ampicillin:** These drugs are not associated with pyloric hypertrophy. Rifampicin is known for causing orange-colored secretions, and Ampicillin is a common cause of antibiotic-associated diarrhea or rashes. **NEET-PG High-Yield Pearls:** * **Clinical Presentation:** IHPS typically presents at 3–6 weeks of age with **non-bilious, projectile vomiting** and a palpable "olive-shaped" mass in the epigastrium. * **Metabolic Profile:** It causes **Hypochloremic, Hypokalemic Metabolic Alkalosis** (due to loss of HCl from the stomach). * **Drug of Choice for Pertussis:** Despite the risk of IHPS, macrolides remain the treatment of choice for Pertussis, but infants must be monitored closely for symptoms of vomiting.

Question 11: What is the maintenance dose of digoxin in a child, expressed in mg/kg?

A. 0.02-0.04
B. 0.03-0.05
C. 0.04-0.06 (Correct Answer)
D. 0.06-0.08

Explanation: **Explanation:** The correct maintenance dose of Digoxin in children is **0.04-0.06 mg/kg/day** (Option C). **1. Underlying Medical Concept:** Pediatric dosing for Digoxin is significantly different from adult dosing due to age-related changes in pharmacokinetics. Children, particularly infants (beyond the neonatal period), require higher doses per kilogram of body weight compared to adults. This is attributed to: * **Larger Volume of Distribution ($V_d$):** Children have a higher percentage of total body water and different tissue binding characteristics, necessitating a higher dose to achieve therapeutic serum concentrations. * **Renal Clearance:** Once the neonatal period passes, renal clearance of Digoxin is relatively efficient in children. **2. Analysis of Options:** * **Option A (0.02-0.04) & B (0.03-0.05):** These ranges are generally too low for the standard pediatric maintenance dose and may result in sub-therapeutic levels, though 0.02-0.03 mg/kg is sometimes considered for preterm neonates who have immature renal function. * **Option D (0.06-0.08):** This range approaches toxic levels. Digoxin has a narrow therapeutic index; doses in this range significantly increase the risk of arrhythmias and gastrointestinal toxicity. **3. High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose:** The Total Digitalizing Dose (TDD) is usually divided into three doses (50% initially, then 25% and 25% at 8-hour intervals). * **Monitoring:** Always monitor serum potassium; **hypokalemia** predisposes the patient to digoxin toxicity because potassium and digoxin compete for the same binding site on the $Na^+/K^+$-ATPase pump. * **Antidote:** Digoxin-specific Fab fragments (Digibind) is the treatment of choice for life-threatening toxicity. * **ECG Change:** The most common initial sign of toxicity in children is often **bradycardia** or AV block, rather than the visual disturbances seen in adults.

Question 12: Which electrolyte imbalance is commonly caused by carbamazepine in elderly patients?

A. Hypernatremia
B. Hyponatremia (Correct Answer)
C. Hyperkalemia
D. Hypokalemia

Explanation: **Explanation:** **Carbamazepine** is a well-known cause of **Hyponatremia** (Option B), particularly in the elderly. This occurs through a mechanism known as **SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion)** or a "vasopressin-like" effect [1]. Carbamazepine increases the sensitivity of the renal collecting duct receptors to ADH and stimulates the release of endogenous ADH [2]. This leads to excessive water reabsorption, resulting in dilutional hyponatremia. Elderly patients are at higher risk due to age-related changes in water homeostasis and the frequent concomitant use of other drugs like diuretics or SSRIs. **Analysis of Incorrect Options:** * **Hypernatremia (A):** Carbamazepine causes water retention, not water loss or sodium gain; therefore, it does not cause hypernatremia. * **Hyperkalemia (C) & Hypokalemia (D):** While carbamazepine primarily affects sodium channels and ADH activity, it does not have a direct or clinically significant effect on potassium levels. Potassium imbalances are more commonly associated with diuretics, ACE inhibitors, or mineralocorticoids. **High-Yield Clinical Pearls for NEET-PG:** * **Oxcarbazepine:** A prodrug of carbamazepine, it is actually associated with a *higher* incidence of hyponatremia than carbamazepine itself. * **Monitoring:** Baseline and periodic serum sodium levels should be monitored in elderly patients starting carbamazepine. * **Other Side Effects:** Remember the "3 Ds" for Carbamazepine: **D**iplopia, **D**izziness, and **D**rowsiness. It is also a potent **Cytochrome P450 enzyme inducer** and can cause **Stevens-Johnson Syndrome** (especially in patients with the HLA-B*1502 allele).

Question 13: Most common cause of Mobius syndrome is the use of which of the following drugs in pregnancy?

A. Misoprostol (Correct Answer)
B. Thalidomide
C. Methotrexate
D. Dinoprostone

Explanation: **Explanation:** **1. Why Misoprostol is the Correct Answer:** Misoprostol is a synthetic prostaglandin E1 (PGE1) analog frequently used off-label as an abortifacient. When used in the first trimester for failed medical abortion, it can cause **vascular disruption** in the developing fetus. The leading theory is that misoprostol-induced uterine contractions lead to transient uterine ischemia, affecting the development of the cranial nerve nuclei (specifically the 6th and 7th nerves). This results in **Mobius Syndrome**, characterized by congenital facial paralysis and impaired ocular abduction (mask-like facies). **2. Why Other Options are Incorrect:** * **Thalidomide:** Classically associated with **Phocomelia** (seal-like limbs), amelia, and internal organ defects. While it can cause ear and eye abnormalities, it is not the primary cause of Mobius syndrome. * **Methotrexate:** A folic acid antagonist that causes **Fetal Hydantoin-like syndrome** or "Methotrexate embryopathy," characterized by skull defects (craniosynostosis), limb malformations, and growth retardation. * **Dinoprostone:** A PGE2 analog used for cervical ripening at term. It is not typically associated with first-trimester teratogenicity or Mobius syndrome, as it is not commonly used for early medical abortions. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mobius Syndrome Triad:** Facial nerve palsy (CN VII), Abducens nerve palsy (CN VI), and often limb defects (e.g., clubfoot). * **Misoprostol Teratogenicity:** Apart from Mobius syndrome, it is also linked to **Terminal Transverse Limb Defects**. * **Safe Alternatives:** For labor induction, Dinoprostone is preferred; for postpartum hemorrhage (PPH), Misoprostol is a key drug. * **Other Vascular Disruptors:** Cocaine and Ergotamine are also associated with vascular-mediated fetal defects.

Question 14: A woman treated with lithium during pregnancy, the fetus should be tested for which of the following?

A. Neural tube defects
B. Cardiac malformations (Correct Answer)
C. Urogenital abnormalities
D. Scalp defects

Explanation: **Explanation:** Lithium is a well-known teratogen, and its use during the first trimester of pregnancy is specifically associated with an increased risk of **cardiac malformations**. The most characteristic defect is **Ebstein’s Anomaly**, which involves the apical displacement of the tricuspid valve leaflets, leading to "atrialization" of the right ventricle and severe tricuspid regurgitation. While the absolute risk is lower than previously thought (approx. 1-2 per 1000), it remains significantly higher than the general population. **Analysis of Incorrect Options:** * **Neural Tube Defects (NTDs):** These are primarily associated with **Valproate** and **Carbamazepine** due to interference with folate metabolism. * **Urogenital Abnormalities:** These are not typically associated with Lithium. Examples include hypospadias, which can be seen with certain anti-androgens or environmental factors. * **Scalp Defects (Aplasia Cutis Congenita):** This is a classic side effect associated with the use of **Methimazole** (anti-thyroid drug) during the first trimester. **High-Yield Clinical Pearls for NEET-PG:** * **Ebstein’s Anomaly:** Look for "atrialization of the right ventricle" in the question stem. * **Lithium in Pregnancy:** If used near term, it can cause **"Floppy Infant Syndrome"** (cyanosis, hypotonia, and poor suckling). * **Monitoring:** Fetal echocardiography is recommended at 18–20 weeks of gestation for mothers taking Lithium. * **Breastfeeding:** Lithium is generally avoided during breastfeeding as it is excreted in milk and can cause neonatal toxicity.

Question 15: Which of the following NSAIDs has been approved for use in children?

A. Indomethacin
B. Ibuprofen (Correct Answer)
C. Ketorolac
D. Piroxicam

Explanation: **Explanation:** **Why Ibuprofen is Correct:** Ibuprofen is one of the most commonly used and safest NSAIDs in pediatric practice. It is FDA-approved for use in children as young as **6 months** of age for its analgesic, anti-inflammatory, and antipyretic properties. Its safety profile is well-established, particularly regarding its lower risk of gastrointestinal and renal side effects compared to other NSAIDs when used at appropriate pediatric doses (5–10 mg/kg). **Analysis of Incorrect Options:** * **Indomethacin (A):** While used in neonates specifically for the medical closure of **Patent Ductus Arteriosus (PDA)**, it is generally avoided for routine pain or fever in children due to a high incidence of severe side effects, including GI bleeding and CNS disturbances. * **Ketorolac (C):** This is a potent analgesic but is generally not recommended for children under **16 years** (except in specific short-term post-operative settings under strict supervision) due to the high risk of renal toxicity and platelet inhibition. * **Piroxicam (D):** This oxicam derivative has a very long half-life (~50 hours), making it difficult to manage in pediatric populations where metabolic rates vary. It is associated with a higher risk of serious skin reactions (Stevens-Johnson Syndrome) and GI toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Aspirin Warning:** Never use Aspirin in children with viral infections (Flu/Chickenpox) due to the risk of **Reye’s Syndrome** (fulminant hepatic failure and encephalopathy). * **Drug of Choice:** **Paracetamol (Acetaminophen)** remains the first-line antipyretic for children; Ibuprofen is the preferred NSAID alternative. * **PDA Management:** Indomethacin or Ibuprofen (IV) can be used to close a PDA, but **Prostaglandin E1 (Alprostadil)** is used to keep it open in cyanotic heart disease.

Question 16: Which of the following NSAIDs has been approved for use in children?

A. Indomethacin
B. Ibuprofen (Correct Answer)
C. Ketorolac
D. Piroxicam

Explanation: **Explanation:** **Correct Answer: B. Ibuprofen** **Medical Concept:** Pediatric pharmacotherapy requires drugs with a high safety profile and well-established dosing guidelines. **Ibuprofen** is one of the most commonly used and safest NSAIDs in children. It is FDA-approved for use in infants as young as **6 months** for its analgesic, anti-inflammatory, and antipyretic properties. It works by reversibly inhibiting COX-1 and COX-2 enzymes. Along with Paracetamol, it is a first-line agent for managing pediatric fever and pain. **Analysis of Incorrect Options:** * **A. Indomethacin:** While used in neonates specifically for the medical closure of **Patent Ductus Arteriosus (PDA)**, it is generally avoided as a routine analgesic/antipyretic in children due to its high incidence of systemic side effects (GI bleed, renal toxicity). * **C. Ketorolac:** This is a potent NSAID primarily used for short-term management of severe post-operative pain. It is generally not recommended for routine use in children under 16 years (or strictly limited to inpatient settings) due to the high risk of gastrointestinal bleeding and renal impairment. * **D. Piroxicam:** This oxicam derivative has a very long half-life (~50 hours), making it difficult to manage in pediatric populations where metabolic rates vary. It is associated with a higher risk of serious skin reactions (Stevens-Johnson Syndrome). **High-Yield NEET-PG Pearls:** * **Aspirin Warning:** Never use Aspirin in children with viral infections (Flu, Chickenpox) due to the risk of **Reye’s Syndrome** (fulminant hepatic failure and encephalopathy). * **Drug of Choice for PDA:** Intravenous **Indomethacin** or **Ibuprofen** (Ibuprofen is often preferred now due to less renal vasoconstriction). * **Safe Age:** Ibuprofen is typically started after 6 months; Paracetamol (Acetaminophen) can be used from birth.

Question 17: Which pharmacokinetic change commonly occurs in geriatric patients?

A. Gastric absorption
B. Liver metabolism
C. Renal clearance (Correct Answer)
D. Hypersensitivity

Explanation: ### Explanation The correct answer is **C. Renal clearance**. **1. Why Renal Clearance is the Correct Answer:** The most predictable and clinically significant pharmacokinetic change in geriatric patients is a **decline in renal function** [1]. Aging is associated with a reduction in renal blood flow, glomerular filtration rate (GFR), and tubular secretion [3]. Even in the absence of overt kidney disease, GFR typically decreases by approximately 1 mL/min per year after age 40 [1]. This leads to a prolonged half-life and increased toxicity risk for drugs primarily excreted by the kidneys (e.g., Digoxin, Aminoglycosides, Lithium) [4]. **2. Analysis of Incorrect Options:** * **A. Gastric Absorption:** While there is a decrease in gastric acid secretion and mucosal surface area in the elderly, the **passive absorption** of most drugs remains largely unaffected. Therefore, it is not a "common" or clinically significant change compared to renal excretion. * **B. Liver Metabolism:** While liver mass and blood flow decrease, Phase II reactions (conjugation) remain relatively preserved [2]. Phase I reactions (oxidation/reduction) may decline, but this is less predictable than the decline in renal clearance [2]. * **D. Hypersensitivity:** This is a **pharmacodynamic** change (how the drug affects the body) rather than a pharmacokinetic change (how the body handles the drug). **3. High-Yield Clinical Pearls for NEET-PG:** * **Cockcroft-Gault Formula:** Always use this to estimate creatinine clearance in the elderly, as serum creatinine alone may remain "normal" due to decreased muscle mass (sarcopenia) [1]. * **Body Composition:** Geriatric patients have **increased body fat** and **decreased total body water** [3]. This increases the volume of distribution ($V_d$) for lipid-soluble drugs (e.g., Diazepam) and decreases $V_d$ for water-soluble drugs (e.g., Digoxin). * **Albumin:** Serum albumin levels often decrease, leading to a higher free fraction of highly protein-bound drugs (e.g., Phenytoin, Warfarin). * **Rule of Thumb:** "Start low and go slow."

Question 18: Which drug may lead to hemolysis in a child with G6PD deficiency?

A. Penicillin
B. Primaquine (Correct Answer)
C. Ceftriaxone
D. Erythromycin

Explanation: **Explanation:** **1. Why Primaquine is Correct:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the levels of **reduced glutathione** in red blood cells. Reduced glutathione acts as an antioxidant, protecting RBCs from oxidative stress. **Primaquine**, an antimalarial used for the radical cure of *P. vivax* and *P. ovale*, is a potent oxidizing agent. In G6PD-deficient individuals, the inability to regenerate glutathione leads to the oxidation of hemoglobin, forming **Heinz bodies**, which results in acute hemolysis and hemoglobinuria. **2. Why Other Options are Incorrect:** * **Penicillin & Ceftriaxone (Beta-lactams):** These drugs are generally safe in G6PD deficiency. While they can occasionally cause immune-mediated hemolytic anemia (Type II hypersensitivity), they do not cause oxidative hemolysis. * **Erythromycin (Macrolide):** This antibiotic is not associated with oxidative stress or hemolysis in G6PD-deficient patients. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other common triggers:** Sulfonamides (Dapsone, Cotrimoxazole), Nitrofurantoin, Nalidixic acid, and Fava beans (Favism). * **Diagnosis:** Peripheral smear shows **"Bite cells"** (degmacytes) and **Heinz bodies** (denatured hemoglobin visible with supravital stains like Crystal Violet). * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder, making it more common in males. * **Screening:** Always screen for G6PD deficiency before initiating Primaquine or Dapsone therapy.

Question 19: What is the most important factor for calculating the dose of NSAIDs in children?

A. Age of the child
B. Body weight of the child (Correct Answer)
C. Flavor of the salt
D. Extent of pain

Explanation: **Explanation:** The correct answer is **B. Body weight of the child.** In pediatric pharmacology, the most reliable and standard method for calculating drug dosages, including NSAIDs (like Ibuprofen or Paracetamol), is based on **body weight (mg/kg)**. This is because children are not merely "small adults"; their physiological processes—including volume of distribution, metabolic rate, and renal clearance—correlate more closely with body mass than chronological age. Using weight ensures that the plasma concentration of the drug remains within the therapeutic window, minimizing the risk of toxicity or sub-therapeutic dosing. **Analysis of Incorrect Options:** * **A. Age of the child:** While age-based rules (e.g., Young’s Rule) exist, they are often inaccurate because children of the same age can have vastly different weights. Age is a poor predictor of metabolic maturity in older children. * **C. Flavor of the salt:** Flavor affects **compliance** (palatability), especially in liquid formulations, but it has no bearing on the pharmacological dose calculation. * **D. Extent of pain:** While the severity of pain may dictate the *choice* of analgesic (e.g., NSAID vs. Opioid), the specific dose of a chosen NSAID must still be calculated based on weight to ensure safety. **High-Yield Clinical Pearls for NEET-PG:** * **Body Surface Area (BSA):** While weight is the most common method, **BSA** is considered the *most accurate* method for calculating doses (especially for chemotherapy), as it correlates better with cardiac output and glomerular filtration rate. * **Aspirin Caution:** Never use Aspirin in children with viral infections (like Flu or Varicella) due to the risk of **Reye’s Syndrome**. * **Ibuprofen Dose:** The standard pediatric dose is **5–10 mg/kg** every 6–8 hours. * **Paracetamol Dose:** The standard pediatric dose is **10–15 mg/kg** every 4–6 hours.

Question 20: Which of the following drugs should be avoided in a 7-year-old child?

A. Cefixime
B. Erythromycin
C. Ofloxacin (Correct Answer)
D. Amoxicillin

Explanation: **Explanation:** **Correct Option: C (Ofloxacin)** Ofloxacin belongs to the **Fluoroquinolone** class of antibiotics. In pediatric patients (typically those under 18 years of age), fluoroquinolones are generally avoided because they can cause **arthropathy and permanent cartilage damage** in weight-bearing joints. Studies in juvenile animals demonstrated that these drugs lead to the erosion of cartilage, which has led to a cautious approach in human clinical practice. While they are used in specific life-threatening conditions (e.g., complicated UTIs or cystic fibrosis exacerbations), they are contraindicated for routine use in a 7-year-old. **Incorrect Options:** * **A & D (Cefixime and Amoxicillin):** These are Beta-lactam antibiotics (Cephalosporin and Penicillin, respectively). They are considered the first-line, safest, and most commonly prescribed antibiotics in pediatrics for various infections. * **B (Erythromycin):** This is a Macrolide antibiotic. While it can cause GI upset or, rarely, hypertrophic pyloric stenosis in neonates, it is generally safe and frequently used in older children (like a 7-year-old) for respiratory infections. **High-Yield Clinical Pearls for NEET-PG:** * **Tetracyclines:** Avoided in children <8 years due to **permanent tooth discoloration** and bone growth retardation. * **Chloramphenicol:** Avoided in neonates due to **Gray Baby Syndrome** (caused by deficient glucuronide conjugation). * **Sulfonamides:** Avoided in newborns as they displace bilirubin from albumin, leading to **Kernicterus**. * **Promethazine:** Contraindicated in children <2 years due to the risk of fatal **respiratory depression**.

Question 21: Which of the following drugs is NOT contraindicated in pregnancy?

A. Chloroquine (Correct Answer)
B. Primaquine
C. Tobramycin
D. ACE inhibitor

Explanation: **Explanation:** The correct answer is **Chloroquine**. In pharmacological management during pregnancy, drugs are categorized based on their teratogenic potential. Chloroquine is considered safe for both the prophylaxis and treatment of malaria in pregnant women across all trimesters. **Why Chloroquine is Correct:** Chloroquine does not have documented teratogenic effects at standard antimalarial doses. Since malaria itself poses a significant risk to both the mother (anemia, hypoglycemia) and the fetus (IUGR, stillbirth), Chloroquine remains the drug of choice where sensitivity exists. **Why the Other Options are Incorrect:** * **Primaquine:** It is strictly contraindicated in pregnancy. It can cross the placenta and cause **severe hemolysis** in the fetus, especially if the fetus has an undetected G6PD deficiency. * **Tobramycin:** As an Aminoglycoside, it is associated with **ototoxicity** (damage to the 8th cranial nerve) in the fetus, potentially leading to congenital deafness. * **ACE Inhibitors (e.g., Enalapril):** These are potent teratogens, particularly in the 2nd and 3rd trimesters. They cause **fetal renal dysgenesis**, oligohydramnios, skull hypoplasia, and intrauterine growth restriction (IUGR). **High-Yield Clinical Pearls for NEET-PG:** * **Safe Antimalarials:** Chloroquine, Quinine, and Clindamycin are generally safe. * **Safe Antihypertensives:** Labetalol (Drug of choice), Methyldopa, and Hydralazine. * **Teratogenic Mnemonic (TERATO):** **T**halidomide (Phocomelia), **E**pileptic drugs (Valproate - Neural tube defects), **R**etinoids (Craniofacial defects), **A**CE inhibitors (Renal damage), **T**etracyclines (Discolored teeth), **O**ther (Warfarin - Fetal Warfarin Syndrome).

Question 22: Closure of a patent ductus arteriosus in a premature infant can be stimulated by the administration of which of the following?

A. Prostaglandin analogue
B. Estrogen
C. Anti-estrogen compounds
D. Prostaglandin inhibitors (Correct Answer)

Explanation: **Explanation:** **Mechanism of Action (Why D is correct):** In fetal life, the **Ductus Arteriosus (DA)** remains open due to high levels of circulating **Prostaglandin E2 (PGE2)**, which acts as a potent vasodilator on the ductal smooth muscle. After birth, PGE2 levels normally drop, leading to functional closure. In premature infants, if the ductus remains patent (PDA), pharmacological closure is achieved by using **Prostaglandin Inhibitors** (NSAIDs). These drugs inhibit the enzyme **Cyclooxygenase (COX)**, thereby decreasing PGE2 synthesis and allowing the ductus to constrict and close. **Analysis of Incorrect Options:** * **A. Prostaglandin analogue (e.g., Alprostadil):** These are used to **maintain** ductal patency in neonates with cyanotic heart disease (e.g., Transposition of Great Arteries) where the PDA is life-sustaining. * **B & C. Estrogen/Anti-estrogens:** These hormonal compounds have no established clinical role in the regulation of ductal tone or the management of PDA. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Traditionally **Indomethacin** was the standard; however, **Ibuprofen** is now often preferred due to a lower risk of renal side effects and necrotizing enterocolitis (NEC). * **Paracetamol (Acetaminophen):** Recent evidence suggests IV Paracetamol is also effective for PDA closure with a better safety profile in some neonates. * **Contraindications for NSAIDs in PDA:** Significant renal impairment, active bleeding (e.g., IVH), or suspected necrotizing enterocolitis. * **Mnemonic:** **"E"** keeps it open (PGE), **"In"** closes it (**In**domethacin).

Question 23: Which drug can be safely used in lactating mothers?

A. Ampicillin
B. Chloramphenicol
C. Ciprofloxacin
D. Erythromycin (Correct Answer)

Explanation: Explanation: The safety of drugs during lactation depends on the drug’s concentration in breast milk and its potential toxicity to the infant [2]. Erythromycin is considered the safest option among the choices provided. It is excreted in breast milk in very small amounts, and the American Academy of Pediatrics (AAP) classifies it as compatible with breastfeeding. While there is a theoretical risk of infantile hypertrophic pyloric stenosis (IHPS) with systemic macrolide use, it remains a preferred choice for maternal infections.Analysis of Incorrect Options: * Chloramphenicol (Option B): It is strictly contraindicated during lactation. It can cause bone marrow suppression in the infant and carries the risk of "Gray Baby Syndrome" due to the infant's immature glucuronidation pathway [1], [3].* Ciprofloxacin (Option C): Fluoroquinolones are generally avoided during breastfeeding due to concerns regarding arthropathy and potential damage to developing cartilage in the infant.* Ampicillin (Option A): While penicillins are generally safe, they are more likely than erythromycin to cause diarrhea, candidiasis, or allergic sensitization in the nursing infant [1].High-Yield Clinical Pearls for NEET-PG: * Safe Antibiotics in Lactation: Penicillins [1], Cephalosporins, and Erythromycin.* Drugs Contraindicated in Lactation: Lithium, Radioactive isotopes, Methotrexate, Ergotamine, and Amiodarone.* Rule of Thumb: Drugs with high molecular weight, high protein binding, and low lipid solubility are less likely to cross into breast milk [2].* Tetracyclines: Usually avoided for long-term use as they may cause dental staining or inhibit bone growth in the infant [2].

Question 24: What is the minimum dose of tetracycline that causes discoloration of teeth?

A. 10 mg/kg body weight
B. 20 mg/kg body weight (Correct Answer)
C. 30 mg/kg body weight
D. 40 mg/kg body weight

Explanation: **Explanation:** The correct answer is **B. 20 mg/kg body weight.** **Underlying Medical Concept:** Tetracyclines are known for their high affinity for calcium ions. They form a stable **tetracycline-calcium orthophosphate complex**, which is deposited in tissues undergoing active calcification, such as developing teeth and bones. When administered during the period of tooth mineralization (from the second trimester of pregnancy to 8 years of age), these complexes cause permanent **yellow-brown discoloration** and enamel hypoplasia. Clinical studies and pharmacological data indicate that a cumulative dose or a daily dose reaching **20 mg/kg** is the threshold at which significant clinical staining becomes evident. **Analysis of Options:** * **A. 10 mg/kg:** This dose is generally considered below the threshold for significant permanent staining, though any exposure during critical periods carries a risk. * **C & D. 30 mg/kg and 40 mg/kg:** While these higher doses will certainly cause discoloration, they are not the *minimum* dose required to trigger the effect. The question specifically asks for the lowest threshold (minimum dose). **High-Yield Clinical Pearls for NEET-PG:** * **Age Contraindication:** Tetracyclines are strictly contraindicated in children below **8 years** of age and in **pregnant women** (after the 4th month of gestation) to avoid dental staining and inhibition of bone growth. * **Exception:** **Doxycycline** is now considered safer than older tetracyclines and can be used for short durations (up to 21 days) in children for specific indications like Rickettsial infections (Rocky Mountain Spotted Fever), as it binds less readily to calcium. * **Mechanism of Discoloration:** The initial yellow stain is fluorescent under UV light; over time, it oxidizes to a non-fluorescent brown color due to light exposure.

Question 25: What is the most dangerous effect of belladonna in very young children?

A. Dehydration
B. Hallucination
C. Hypertension
D. Hyperthermia (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Hyperthermia** Belladonna alkaloids (like Atropine and Scopolamine) are competitive antagonists of muscarinic receptors. In children, the most dangerous effect is **Atropine Fever** or severe hyperthermia. This occurs due to two primary mechanisms: 1. **Suppression of Sweating:** Atropine blocks $M_3$ receptors on eccrine sweat glands (which are under sympathetic cholinergic control). This inhibits evaporative heat loss. 2. **Central Effect:** It acts on the hypothalamus to dysregulate the body’s thermostat. Children are particularly susceptible because their surface-area-to-body-mass ratio is high, and their thermoregulatory centers are less mature. In toxic doses, this can lead to fatal hyperpyrexia. **Analysis of Incorrect Options:** * **A. Dehydration:** While belladonna causes "dryness" (dry mouth, dry eyes), it does not cause systemic fluid loss or dehydration. The danger arises from the inability to sweat, not the loss of body fluids. * **B. Hallucination:** Central nervous system effects like "Atropine madness" (delirium, hallucinations) are common in toxicity, but they are rarely life-threatening compared to the metabolic crisis of hyperthermia. * **C. Hypertension:** Atropine typically causes tachycardia. While a slight rise in blood pressure may occur due to increased heart rate, it is not the primary or most dangerous pediatric complication. **NEET-PG High-Yield Pearls:** * **Mnemonic for Atropine Poisoning:** "Red as a beet (flushing), Dry as a bone (anhidrosis), Blind as a bat (mydriasis), Mad as a hatter (delirium), and **Hot as a hare (hyperthermia)**." * **Antidote:** **Physostigmine** (a tertiary amine carbamate) is the drug of choice for belladonna poisoning as it crosses the blood-brain barrier to reverse both central and peripheral effects. * **Contraindication:** Atropine is contraindicated in patients with narrow-angle glaucoma and prostatic hypertrophy.

Question 26: All are reasons for alteration of drug dosage in the elderly except:

A. Decreasing renal function with age
B. Lean body mass is less
C. Increased baroreceptor sensitivity (Correct Answer)
D. Decreased body water

Explanation: In geriatric pharmacology, the physiological changes associated with aging significantly alter the pharmacokinetics and pharmacodynamics of drugs. ### **Explanation of the Correct Answer** **Option C (Increased baroreceptor sensitivity)** is the correct answer because it is a **false statement**. In reality, elderly patients experience **decreased baroreceptor sensitivity**. * **The Concept:** The baroreceptor reflex is responsible for maintaining blood pressure during postural changes. In the elderly, this reflex is blunted. When drugs like antihypertensives, TCAs, or diuretics are administered, the body cannot compensate for the drop in pressure by increasing heart rate effectively. This leads to an increased risk of **orthostatic hypotension** and falls, necessitating cautious dosing. ### **Analysis of Incorrect Options** * **A. Decreasing renal function:** This is the most important pharmacokinetic change in the elderly. GFR declines even in the absence of kidney disease. Since many drugs are renally excreted, doses must be reduced to prevent toxicity (e.g., Digoxin, Aminoglycosides). * **B. Lean body mass is less:** Aging is associated with "Sarcopenia" (loss of muscle mass). This reduces the volume of distribution ($V_d$) for drugs that bind to muscle tissue (e.g., Digoxin). * **D. Decreased body water:** Total body water decreases while body fat increases. This leads to a **decreased $V_d$ for water-soluble drugs** (higher plasma concentration) and an **increased $V_d$ for lipid-soluble drugs** (prolonged half-life, e.g., Diazepam). ### **High-Yield Clinical Pearls for NEET-PG** * **Serum Creatinine Trap:** In the elderly, serum creatinine may appear normal despite low GFR because of reduced muscle mass. Always calculate **Creatinine Clearance** ($CrCl$) using the Cockcroft-Gault formula. * **Phase I vs. Phase II Metabolism:** Phase I (Oxidation/Reduction) is significantly reduced with age, while **Phase II (Conjugation)** remains relatively preserved. * **Beers Criteria:** A clinical guideline used to identify "Potentially Inappropriate Medications" in the elderly (e.g., avoiding long-acting benzodiazepines).

Question 27: Which drug is implicated for prolonging the QT interval in a premature baby?

A. Domperidone
B. Metoclopramide
C. Cisapride (Correct Answer)
D. Omeprazole

Explanation: **Explanation:** **Cisapride** is a prokinetic agent that acts as a serotonin (5-HT4) receptor agonist. It was historically used for gastroesophageal reflux disease (GERD) in infants. However, it is notorious for causing **QT interval prolongation** and life-threatening ventricular arrhythmias like **Torsades de Pointes**. This occurs because Cisapride blocks the **hERG (human Ether-à-go-go-Related Gene) potassium channels** in the heart, delaying ventricular repolarization. Premature babies are at higher risk due to immature hepatic metabolism (CYP3A4), leading to toxic drug accumulation. **Analysis of Incorrect Options:** * **Domperidone (A):** While it can also prolong the QT interval (especially at high doses or IV), it is generally considered safer than Cisapride and is not the "classic" drug implicated in pediatric QT prolongation in exam scenarios. * **Metoclopramide (B):** This D2-receptor antagonist is associated with extrapyramidal side effects (dystonias) in children, rather than cardiac arrhythmias. * **Omeprazole (D):** A Proton Pump Inhibitor (PPI) that is generally safe regarding cardiac conduction; its primary concerns in neonates are increased risk of infections (NEC or pneumonia). **High-Yield Clinical Pearls for NEET-PG:** * **Drug Interaction:** Cisapride toxicity is significantly increased when co-administered with **CYP3A4 inhibitors** (e.g., Erythromycin, Ketoconazole). * **Regulatory Status:** Due to the risk of sudden cardiac death, Cisapride has been withdrawn or highly restricted in most global markets. * **Other QT-prolonging drugs:** Macrolides, Fluoroquinolones, Antipsychotics (Haloperidol), and Class IA/III Anti-arrhythmics.

Question 28: A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

A. Prostaglandin analogue
B. Estrogen
C. Anti-estrogen compounds
D. Prostaglandin inhibitors (Correct Answer)

Explanation: The **Patent Ductus Arteriosus (PDA)** is a physiological shunt in the fetus that connects the pulmonary artery to the aorta, bypassing the non-functional lungs. Its patency is maintained by high levels of circulating **Prostaglandin E2 (PGE2)**, which is produced by the placenta and the ductal tissue itself [1]. **1. Why Prostaglandin Inhibitors are Correct:** After birth, the ductus normally closes due to increased oxygen tension and a drop in PGE2 levels [1]. In premature infants where the ductus remains open, administration of **Prostaglandin Inhibitors** (specifically NSAIDs like **Indomethacin** or **Ibuprofen**) inhibits the enzyme cyclooxygenase (COX). This reduces PGE2 synthesis, leading to the constriction and functional closure of the ductus. **2. Why the other options are incorrect:** * **Prostaglandin analogues (e.g., Alprostadil):** These are used to **keep the ductus open** (maintain patency) in neonates with ductal-dependent congenital heart defects (e.g., Transposition of Great Arteries) until surgery can be performed [1]. * **Estrogen and Anti-estrogen compounds:** These hormonal agents have no established clinical role in the physiological or pharmacological closure of the ductus arteriosus. **3. Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Indomethacin was traditionally the gold standard, **Ibuprofen** is often preferred now due to a lower risk of renal side effects and necroitizing enterocolitis. * **Paracetamol:** Recent evidence suggests intravenous Paracetamol is also effective for PDA closure with fewer contraindications. * **Contraindication:** Prostaglandin inhibitors (NSAIDs) should be avoided in the third trimester of pregnancy to prevent **premature closure** of the ductus in utero, which can lead to primary pulmonary hypertension in the newborn.

Question 29: A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

A. Prostaglandin analogue
B. Estrogen
C. Anti-estrogen compounds
D. Prostaglandin inhibitors (Correct Answer)

Explanation: **Explanation:** The patency of the **Ductus Arteriosus (DA)** in utero is actively maintained by high levels of circulating **Prostaglandins (specifically PGE2)**, which are produced by the placenta and the ductal tissue itself. PGE2 acts on EP4 receptors to cause vasodilation of the ductal smooth muscle. **Why the correct answer is right:** At birth, PGE2 levels normally fall, leading to functional closure of the ductus. In premature infants, if the ductus remains patent (PDA), pharmacological closure can be achieved by administering **Prostaglandin Inhibitors**, specifically non-selective **NSAIDs** like **Indomethacin** or **Ibuprofen**. These drugs inhibit the enzyme Cyclooxygenase (COX), thereby decreasing PGE2 synthesis and allowing the ductus to constrict and close. **Why the incorrect options are wrong:** * **A. Prostaglandin analogue:** Administering PGE1 (Alprostadil) would keep the ductus *open*. This is clinically indicated in cyanotic heart diseases (e.g., Transposition of Great Arteries) where a PDA is life-saving. * **B & C. Estrogen/Anti-estrogen:** These hormonal compounds have no direct physiological role in the acute contraction or relaxation of the ductus arteriosus smooth muscle. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen** is often preferred now due to a lower risk of renal side effects and necrotizing enterocolitis (NEC). * **Alternative:** Recent studies suggest **Paracetamol (Acetaminophen)** is also effective for PDA closure with fewer side effects. * **Mnemonic:** To **K**eep the ductus open, give PGE (Alprostadil). To **C**lose it, give **C**OX inhibitors (Indomethacin).

Question 30: All of the following are reasons for reducing drug dosage in the elderly, EXCEPT:

A. Lean body mass and low body fat
B. Reduced renal function with age
C. Increased baroceptor sensitivity (Correct Answer)
D. Reduced hepatic metabolism

Explanation: In geriatric pharmacology, the physiological changes associated with aging generally necessitate a reduction in drug dosage to avoid toxicity. [2] **Why Option C is the Correct Answer:** In the elderly, there is actually a **decrease** (blunting) of baroreceptor sensitivity. This means the body’s compensatory mechanism to maintain blood pressure during postural changes is impaired. Consequently, elderly patients are highly susceptible to **orthostatic (postural) hypotension**, especially when taking antihypertensives, diuretics, or TCAs. [3] Since the option states "increased" sensitivity, it is the incorrect physiological statement and thus the correct answer to the "EXCEPT" question. **Analysis of Incorrect Options:** * **A. Lean body mass and low body fat:** Aging is characterized by a decrease in total body water and lean body mass, while the **proportion of body fat increases**. This alters the volume of distribution ($V_d$); water-soluble drugs (e.g., Digoxin) have a smaller $V_d$, leading to higher plasma concentrations, requiring dose reduction. [4] * **B. Reduced renal function:** This is the most predictable change in the elderly. Glomerular filtration rate (GFR) and tubular secretion decline significantly, leading to the accumulation of renally excreted drugs (e.g., Aminoglycosides, Lithium). [4] * **D. Reduced hepatic metabolism:** Hepatic blood flow and mass decrease with age. Phase I reactions (oxidation/reduction) are often impaired, slowing the clearance of drugs like Diazepam and Theophylline. [1] **High-Yield Clinical Pearls for NEET-PG:** * **The "Golden Rule":** "Start low and go slow" when prescribing for the elderly. * **Serum Creatinine Trap:** In the elderly, serum creatinine may remain within "normal" limits due to reduced muscle mass, even if GFR is significantly reduced. Always calculate **Creatinine Clearance (CrCl)**. [2] * **Phase II Reactions:** Conjugation (Glucuronidation) is generally better preserved in the elderly than Phase I reactions. [1] * **Increased Sensitivity:** The elderly show increased CNS sensitivity to benzodiazepines and opioids, even at lower plasma levels.

Question 31: A 1-year-old child with moderate VSD is scheduled for surgery next month. For control of symptoms of CHF, a drug $X$ was given. The uneducated parents gave double the dose of drug resulting in the child developing listlessness and poor feeding. Based on the ECG shown, what is the drug prescribed and its side effect?

A. Spironolactone, hypokalemia
B. Digoxin toxicity, ventricular bigeminy (Correct Answer)
C. Furosemide, hypokalemia
D. Beta blocker, third-degree heart block

Explanation: ***Digoxin toxicity, ventricular bigeminy*** - The ECG shows a regular rhythm with alternating normal sinus beats and **premature ventricular contractions (PVCs)**, indicating **ventricular bigeminy**. This is a classic arrhythmia associated with **digoxin toxicity**, especially in a child being treated for CHF. - **Digoxin** is commonly used in pediatric CHF to improve myocardial contractility, and overdose (as suggested by double dosing) can lead to symptoms like **listlessness and poor feeding** due to its narrow therapeutic window and central nervous system effects. *Spironolactone, hypokalemia* - **Spironolactone** is a potassium-sparing diuretic and would primarily cause **hyperkalemia**, not hypokalemia. - While used in CHF, it primarily acts on renal electrolyte balance and would not directly cause ventricular arrhythmias like bigeminy. *Furosemide, hypokalemia* - **Furosemide** is a loop diuretic that can cause **hypokalemia**, which is indeed a risk factor for arrhythmias, but the ECG pattern of **bigeminy** is more specific to **digoxin toxicity**. - While hypokalemia *can* predispose to arrhythmias, furosemide itself is not directly indicated by the bigeminy pattern; the symptoms of toxicity (listlessness, poor feeding) for furosemide overdose would primarily involve dehydration and electrolyte imbalances, not specifically cardiac rhythm disturbances like bigeminy. *Beta blocker, third-degree heart block* - **Beta-blockers** are used in some forms of CHF but an overdose typically causes **bradycardia** and **varying degrees of AV block**, potentially a third-degree heart block, but not **ventricular bigeminy**. - The ECG does not show dissociated P waves and QRS complexes characteristic of third-degree heart block; instead, it shows a patterned alternation of normal and ectopic beats.

Question 32: A neonate presents with a congenital heart disease as shown below. Which drug should be started immediately? (Recent NEET Pattern 2016-17)

A. Digoxin
B. Ivabradine
C. Propranolol
D. Alprostadil (Correct Answer)

Explanation: ***Alprostadil*** - The image shows a **transposition of the great arteries (TGA)** with the aorta originating from the right ventricle and the pulmonary artery from the left ventricle. In this condition, a patent ductus arteriosus (PDA) is crucial to maintain mixing of oxygenated and deoxygenated blood to ensure systemic circulation. - **Alprostadil (prostaglandin E1 analog)** is used to keep the **ductus arteriosus patent**, allowing for mixing of blood and improving systemic oxygenation in neonates with ductal-dependent congenital heart defects like severe TGA. *Digoxin* - **Digoxin** is a cardiac glycoside used to improve **cardiac contractility** and control heart rate in certain heart conditions, but it is not the immediate drug of choice for maintaining patency of the ductus arteriosus in TGA. - Its primary role is in managing heart failure symptoms or arrhythmias, not directly addressing the immediate ductal dependency of TGA. *Ivabradine* - **Ivabradine** is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker that selectively reduces heart rate by acting on the **sinoatrial node**. - It is used in adults with chronic heart failure or stable angina, and is not indicated for the acute management of congenital heart defects like TGA in neonates. *Propranolol* - **Propranolol** is a non-selective beta-blocker used to reduce heart rate and blood pressure, or to manage conditions like **tetralogy of Fallot spells**. - It does not have any role in maintaining the patency of the ductus arteriosus, which is critical for survival in ductal-dependent congenital heart lesions like TGA.

Question 33: A 3-year-old child presents with febrile seizures. All of the following are correct about rectal administration of diazepam except:

A. Rate of drug delivery can be controlled
B. Attach soft plastic tube to syringe and push diazepam as prescribed
C. With child on side separate the buttocks and insert lubricated tubing up to distance of 5 cm and inject the drug (Correct Answer)
D. Remove tubing and hold buttock together

Explanation: ***With child on side separate the buttocks and insert lubricated tubing up to distance of 5 cm and inject the drug*** - This statement is incorrect because for **rectal administration** in children, the lubricated tubing or applicator should be inserted only 2-3 cm (about 1 inch) into the anus to ensure drug delivery into the **rectum** without being expelled. - Inserting it up to 5 cm in a 3-year-old could be too deep, potentially causing discomfort or leading to drug administration into the colon, which might alter absorption. *Rate of drug delivery can be controlled* - The **rate of drug delivery** for rectal administration, especially with solutions or gels, can be controlled by how quickly the syringe plunger is depressed, allowing for a gradual administration. - This control helps prevent discomfort and ensures proper absorption by minimizing expulsion. *Attach soft plastic tube to syringe and push diazepam as prescribed* - For **rectal diazepam**, a soft plastic tube or applicator is typically attached to the syringe, aiding in safe and effective insertion into the rectum. - The medication is then administered as prescribed, which is a standard procedure for treating **febrile seizures**. *Remove tubing and hold buttock together* - After administering the medication, the tubing should be carefully **removed**. - **Holding the buttocks together** for a few minutes helps retain the medication in the rectum, optimizing absorption and preventing immediate expulsion.

Question 34: Which of the following statements are correct about oral rotavirus vaccines? I. The storage should be at 2-8°C II. The vaccine should be used within 2 hours of reconstitution or opening III. Past history of intussusception is a contraindication IV. The vaccine can be given if the baby has ongoing diarrhoea Select the answer using the code given below :

A. I and II
B. I and III (Correct Answer)
C. II and IV
D. III and IV

Explanation: ***I and III*** * **Oral rotavirus vaccines** require storage at **2-8°C** to maintain potency (cold chain maintenance is essential). * A past history of **intussusception** is an **absolute contraindication** due to increased risk of recurrence. *I and II* * While statement I is correct, statement II is incorrect because oral rotavirus vaccines (Rotarix, RotaTeq) are **ready-to-use liquid formulations** that do **not require reconstitution**. Once the container is opened, the vaccine should be **administered immediately** during the same vaccination visit, not stored for 2 hours. *II and IV* * Statement II is incorrect as oral rotavirus vaccines are **ready-to-use** and should be **administered immediately** after opening, without any reconstitution. * Statement IV is incorrect because the vaccine **should be postponed** if the baby has ongoing **moderate to severe diarrhoea** or vomiting, as this may affect vaccine absorption and effectiveness. Mild diarrhea is not a contraindication, but significant gastroenteritis warrants deferral. *III and IV* * While statement III is correct, statement IV is incorrect because ongoing **moderate to severe diarrhoea** is a reason to **postpone** administration of the rotavirus vaccine until the child recovers.

Question 35: Which of the following statements are correct regarding management of hyperkalemia in a child? I. Intravenous calcium (gluconate or chloride) is given to enhance cellular uptake of potassium II. Beta adrenergic agonists (salbutamol or terbutaline) are used to stabilize myocardial cell membrane III. Regular insulin and glucose given intravenously enhance cellular uptake of potassium IV. Sodium polystyrene sulfonate enhances total body potassium elimination Select the answer using the code given below :

A. I and II
B. III and IV (Correct Answer)
C. II and III
D. I and IV

Explanation: ***III and IV*** - Intravenous **regular insulin and glucose** work by promoting the intracellular shift of potassium, thereby lowering serum potassium levels. Insulin stimulates the Na+-K+ ATPase pump, moving potassium into cells, and glucose is given to prevent **hypoglycemia**. - **Sodium polystyrene sulfonate (SPS)** is a cation exchange resin that binds potassium in the gastrointestinal tract and promotes its excretion in the stool, thus enhancing **total body potassium elimination**. *I and II* - Intravenous calcium (gluconate or chloride) is given to **stabilize the myocardial cell membrane**, reducing the risk of arrhythmias, not to enhance cellular uptake of potassium. - Beta-adrenergic agonists like **salbutamol** or **terbutaline** promote the intracellular shift of potassium, similar to insulin, but they **do not stabilize the myocardial cell** membrane. *II and III* - Beta-adrenergic agonists **(salbutamol or terbutaline)** promote the cellular uptake of potassium, but they do not stabilize the myocardial cell membrane; that is the role of calcium. - While regular insulin and glucose given intravenously do enhance cellular uptake of potassium, the statement regarding beta-adrenergic agonists is incorrect in its function to stabilize the myocardial cell membrane. *I and IV* - Intravenous calcium (gluconate or chloride) is administered to **protect the heart** from the effects of hyperkalemia by stabilizing the myocardial cell membrane, not to enhance cellular uptake of potassium. - Although sodium polystyrene sulfonate (SPS) correctly enhances total body potassium elimination, the initial statement regarding calcium's mechanism of action is incorrect.

Question 36: For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is

A. 20 mg
B. 40 mg (Correct Answer)
C. 10 mg
D. 30 mg

Explanation: ***40 mg*** - Miltefosine dosage for children weighing 12 to 29 kg (including a 15 kg child) is typically **2.5 mg/kg body weight per day orally**. - For a 15 kg child, this translates to 2.5 mg/kg * 15 kg = **37.5 mg**, which is rounded to **40 mg** for practical dosing since miltefosine capsules come in 10 mg or 50 mg sizes. *20 mg* - This dose is lower than the recommended **2.5 mg/kg/day** for a 15 kg child, which would be 37.5 mg. - An underdose of miltefosine could lead to **treatment failure** and the development of drug resistance. *10 mg* - This dose is significantly lower than the recommended therapeutic dose for a 15 kg child, which requires approximately **37.5 mg daily**. - Such a low dose would be **ineffective** in treating kala-azar, risking worsening disease. *30 mg* - While closer than 10 mg or 20 mg, 30 mg is still below the calculated **37.5 mg/day** for a 15 kg child. - An insufficient dose may compromise the efficacy of treatment and lead to **suboptimal parasitic clearance**.

Question 37: What is the correct daily dose of Iron and Folic acid to be prescribed to a child aged 12 years?

A. 30 mg elemental Iron and 250 mcg folic acid
B. 20 mg elemental Iron and 100 mcg folic acid
C. 100 mg elemental Iron and 500 mcg folic acid
D. 60 mg elemental Iron and 300 mcg folic acid (Correct Answer)

Explanation: ***60 mg elemental Iron and 300 mcg folic acid*** - This is the **standard daily prophylactic dose** recommended for children aged 10-19 years (adolescents) in India as per **WIFS (Weekly Iron and Folic Acid Supplementation) program** when given daily. - Aligns with **ICMR and National Iron+ Initiative** guidelines for daily supplementation in adolescents. - This dose provides adequate iron for growth requirements and prevention of **nutritional anemia** in this age group. *20 mg elemental Iron and 100 mcg folic acid* - This dose is **too low** for a 12-year-old child and does not meet the iron requirements for adolescents. - This might be appropriate for younger children (6-59 months) but is **inadequate for adolescent growth and development**. - Would not effectively prevent iron deficiency anemia in this age group. *100 mg elemental Iron and 500 mcg folic acid* - This is the dose recommended for **weekly prophylactic supplementation** under the WIFS program, not for daily use. - When used daily, this dose may be used for **treatment of established iron deficiency anemia** rather than routine prophylaxis. - Daily use at this dose may cause **gastrointestinal side effects** like nausea and constipation. *30 mg elemental Iron and 250 mcg folic acid* - This dose is **intermediate but not standard** as per Indian guidelines for this age group. - Does not align with recommended protocols for adolescent supplementation. - Provides suboptimal iron for the growth spurt and increased requirements in 12-year-olds.

Question 38: Least teratogenic antiepileptic drug in pregnancy is:

A. Carbamazepine
B. Valproate
C. Levetiracetam (Correct Answer)
D. Phenytoin

Explanation: ***Levetiracetam*** - **Levetiracetam** is generally considered one of the **safest antiepileptic drugs (AEDs)** during pregnancy, with a lower risk of major congenital malformations compared to other AEDs. - Studies have shown a **low incidence of neural tube defects** and other severe malformations when used as monotherapy. *Carbamazepine* - **Carbamazepine** is associated with an increased risk of **neural tube defects**, particularly **spina bifida**, during pregnancy. - It can also cause other malformations such as **facial dysmorphism** and developmental delays. *Valproate* - **Valproate** has the **highest teratogenic potential** among common AEDs, linked to a significantly increased risk of **neural tube defects**, **cardiac anomalies**, and **cognitive impairment (fetal valproate syndrome)**. - Due to its high risk, its use is generally **contraindicated in women of childbearing potential** unless no other effective alternative exists. *Phenytoin* - **Phenytoin** is associated with **fetal hydantoin syndrome**, characterized by specific facial features, **growth deficiency**, developmental delay, and increased risk of cleft lip/palate, and **cardiac defects**. - It is known for its **dose-dependent teratogenicity**, making careful monitoring crucial.

Question 39: Prophylactic dose of Oseltamivir for infants (3-11 months) is?

A. 3 mg/kg/day (Correct Answer)
B. 5 mg/kg/day
C. 1 mg/kg/day
D. 7 mg/kg/day

Explanation: ***3 mg/kg/day*** - The recommended **prophylactic dose of oseltamivir** for infants aged 3 to 11 months is **3 mg/kg once daily** for 10 days. - This dosage is essential for preventing **influenza** in this vulnerable age group when exposure is known or highly suspected. *5 mg/kg/day* - A dose of **5 mg/kg** is generally used for **treatment** of influenza in infants and children, not for prophylaxis. - This higher dose is administered twice daily for 5 days when a child is already symptomatic. *1 mg/kg/day* - This dosage is **too low** for either prophylactic or treatment use in infants and would likely be ineffective against influenza. - Sub-optimal dosing can lead to **treatment failure** and a higher risk of complications. *7 mg/kg/day* - This dosage is **higher than recommended** for prophylaxis and could potentially lead to increased adverse effects without offering additional benefit. - Higher doses are usually reserved for **severely immunocompromised** patients or specific treatment regimens, not standard prophylaxis.

Question 40: For a child 3-5 months of age with H1N1, treatment Oseltamivir dose is

A. 12 mg BD X 5 days
B. 25 mg BD X 5 days
C. 20 mg OD X 5 days
D. 20 mg BD X 5 days (Correct Answer)

Explanation: ***20 mg BD X 5 days*** - For infants aged **3-5 months** with H1N1 influenza, the recommended dose of **Oseltamivir** is **20 mg twice daily** (BD) for **5 days**. This dosage is based on weight-based recommendations to ensure appropriate antiviral activity. - This treatment regimen is crucial for reducing the severity and duration of influenza symptoms in this vulnerable age group and should be initiated as early as possible. *12 mg BD X 5 days* - This dosage is typically recommended for younger infants, specifically those aged **less than 1 month up to 2 months** (up to 3 kg body weight). - It is **underdosing** for a child in the 3-5 months age range, which could lead to suboptimal antiviral effect. *25 mg BD X 5 days* - This dosage is generally used for children weighing **between 15 kg and 23 kg**, which is significantly higher than the average weight for an infant aged 3-5 months. - Administering this dose to a 3-5 month old would constitute an **overdose**, potentially leading to increased side effects such as nausea, vomiting, or other adverse reactions. *20 mg OD X 5 days* - While 20 mg is the correct single dose, giving it **once daily (OD)** is incorrect for treating H1N1 influenza in infants. - Oseltamivir requires a **twice-daily (BD)** regimen to maintain therapeutic drug levels and effectively inhibit viral replication over the 24-hour period.

Question 41: American Heart Association standard pediatric dose of amoxicillin for antibiotic prophylaxis, in cases of endocarditis is

A. 20mg/kg
B. 125mg/kg
C. 100mg/kg
D. 50mg/kg (Correct Answer)

Explanation: ***50mg/kg*** - The **American Heart Association (AHA)** guidelines recommend **50 mg/kg** of amoxicillin as the standard pediatric dose for antibiotic prophylaxis against infective endocarditis before certain dental procedures. - This dose is typically given orally, as a single dose, 30-60 minutes before the procedure. *20mg/kg* - This dose is lower than the recommended **AHA guideline** for infective endocarditis prophylaxis in children. - Administering this dose could result in **subtherapeutic levels**, failing to adequately prevent bacterial colonization and infection. *125mg/kg* - This dosage is significantly higher than the standard **AHA recommendation** for endocarditis prophylaxis. - Such a high dose could increase the risk of **adverse effects** without providing additional prophylactic benefit. *100mg/kg* - While higher than the standard 50mg/kg, this dose also exceeds the **AHA guidelines** for pediatric endocarditis prophylaxis. - Overdosing can lead to increased **gastrointestinal side effects** and other unwanted drug reactions.

Question 42: Newborns as compared to adults eliminate lidocaine:

A. Variable
B. More rapidly
C. Equally fast
D. More slowly (Correct Answer)

Explanation: ***More slowly*** - Newborns have **immature hepatic enzyme systems**, particularly for **CYP1A2** and **CYP3A4**, which are crucial for lidocaine metabolism. - Reduced **plasma protein binding** and a larger **volume of distribution** in newborns can also impact lidocaine clearance, leading to slower elimination. *Variable* - While there can be individual variability in drug metabolism, the general trend for lidocaine elimination in newborns is consistently slower due to physiological immaturity, not merely variable. - This option does not capture the overall physiological characteristic of drug elimination in neonates. *More rapidly* - This is incorrect because newborns have underdeveloped liver function and enzyme systems, which would hinder, not accelerate, the metabolism and elimination of drugs like lidocaine. - A more rapid elimination would suggest a highly efficient metabolic pathway, which is not the case in neonates. *Equally fast* - This is incorrect as the **pharmacokinetic profile** of drugs, including lidocaine, differs significantly between newborns and adults due to developmental differences in organ function (e.g., liver, kidneys). - The liver's metabolic capacity in newborns is not fully mature enough to eliminate lidocaine at the same rate as in adults.

Question 43: What is the recommended intramuscular (IM) dose of midazolam in children?

A. 0.5 mg/kg
B. 2.5 mg/kg
C. 0.25 mg/kg
D. 0.1 mg/kg (Correct Answer)

Explanation: ***0.1 mg/kg*** - For **intramuscular (IM) administration** in children, the recommended dose of **midazolam for procedural sedation** is typically **0.1-0.15 mg/kg** (maximum 10 mg). - This dose provides **effective sedation** with a favorable safety profile, minimizing the risk of respiratory depression. - This is the **standard dose cited in pediatric pharmacology** references for IM premedication and sedation. *0.25 mg/kg* - A dose of **0.25 mg/kg** IM is **higher than the standard sedation dose** but may be used in specific contexts such as management of acute seizures. - For routine procedural sedation, this dose is **higher than necessary** and increases the risk of adverse effects including respiratory depression. - This dose approaches the range used for **buccal/intranasal midazolam** in status epilepticus (0.2-0.3 mg/kg). *0.5 mg/kg* - A dose of **0.5 mg/kg** IM is **excessively high** for standard procedural sedation in children. - This dose significantly **exceeds recommended guidelines** and carries substantial risk of profound sedation, respiratory depression, and prolonged recovery time. - Such high doses are **not recommended** for routine IM sedation in pediatric practice. *2.5 mg/kg* - A dose of **2.5 mg/kg** IM would be **dangerously high** and could lead to life-threatening respiratory depression, cardiovascular compromise, and prolonged unconsciousness. - This dosage is **far outside the therapeutic range** and represents a potential fatal overdose in pediatric patients.

Question 44: Recommended dose of Oseltamivir for a 9 month old baby for treating swine flu is:

A. 3.5 mg/ kg twice daily for five days
B. 2.5 mg/ kg twice daily for five days
C. 2 mg/ kg twice daily for five days
D. 3 mg/ kg twice daily for five days (Correct Answer)

Explanation: ***3 mg/ kg twice daily for five days*** - For children aged **<1 year** (including a 9-month-old baby), the recommended dose of **oseltamivir** for treating **influenza (swine flu)** is **3 mg/kg** orally twice daily for 5 days. - This dosage is based on pharmacokinetic and clinical data to ensure effective antiviral concentrations in young children. *3.5 mg/ kg twice daily for five days* - This dosage of **oseltamivir** exceeds the recommended guidelines for infants and young children and could potentially increase the risk of adverse effects. - While slight variations might exist in specific patient cases or guidelines, this is generally not the standard recommended dose. *2.5 mg/ kg twice daily for five days* - This dosage of **oseltamivir** is below the generally recommended therapeutic dose for infants <1 year old. - An inadequate dose might lead to suboptimal antiviral efficacy, potentially prolonging viral shedding or clinical symptoms. *2 mg/ kg twice daily for five days* - This dose is typically too low for effective treatment of **influenza** in the 9-month-old age group. - Lower doses might be used for **prophylaxis**, but for active treatment, a higher dose is usually required to adequately suppress viral replication.

Question 45: What is the drug of choice for acute treatment of febrile seizures?

A. Phenobarbitone
B. Diazepam (Correct Answer)
C. Valproate
D. Carbamazepine

Explanation: ***Diazepam*** - **Diazepam** is the drug of choice for the acute treatment of febrile seizures because of its **rapid onset of action** and effectiveness in stopping ongoing seizures [1]. - It is often administered **rectally** or intramuscularly in an emergency setting by parents or caregivers, which is crucial given the urgency of treating a seizure [1]. *Phenobarbitone* - While **phenobarbitone** has anticonvulsant properties, it is typically used for **long-term prophylaxis** in children with recurrent or high-risk febrile seizures, not for acute treatment. - It has a **slower onset of action** and can cause **sedation**, making it less suitable for immediate seizure termination [3]. *Valproate* - **Valproate** is an antiepileptic drug used for various seizure types but is generally **not recommended for acute treatment of febrile seizures** due to its slower onset and potential side effects in young children [2]. - Its use is more relevant in epilepsy management and **long-term seizure prevention**, not as a first-line agent for acute febrile seizure termination [2]. *Carbamazepine* - **Carbamazepine** is primarily used for **focal seizures** and **trigeminal neuralgia** and is not indicated for the acute management of febrile seizures [2]. - It has a **slower onset** and a different mechanism of action that is not optimal for rapidly stopping a febrile seizure.

Question 46: Which of the following is/are 1st line antitubercular drugs for children?

A. Pyrazinamide
B. Isoniazid
C. All of the options (Correct Answer)
D. Rifampicin

Explanation: ***Correct: All of the options*** All three drugs listed are **first-line antitubercular drugs** for children according to WHO and national tuberculosis treatment guidelines. **Isoniazid (H)** - Cornerstone first-line drug with potent **bactericidal activity** against actively dividing Mycobacterium tuberculosis - Highly effective and well-tolerated in children - Essential component of all standard anti-TB regimens **Rifampicin (R)** - Powerful first-line agent with **rapid bactericidal action** and sterilizing activity - Critical for shortening treatment duration - Key drug in both intensive and continuation phases **Pyrazinamide (Z)** - Important first-line drug that is **highly active in acidic environments** - Particularly effective against semi-dormant bacilli - Essential during the intensive phase to shorten treatment duration **Standard Pediatric TB Regimen:** The WHO-recommended first-line regimen for drug-sensitive TB in children includes all four first-line drugs: **Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E)**. Since all the listed options are first-line drugs, "All of the options" is the correct answer.

Question 47: The preferred drug for treating ADHD in a 7-year-old boy, whose father has a history of substance abuse:

A. Clonidine
B. Atomoxetine (Correct Answer)
C. Dexamphetamine
D. Methylphenidate

Explanation: ***Atomoxetine*** - As a **non-stimulant**, atomoxetine is preferred in patients where stimulant use is contraindicated or when there's a concern for **substance abuse potential**, such as a parental history. - It specifically inhibits the **norepinephrine transporter**, leading to increased norepinephrine levels in the prefrontal cortex, improving ADHD symptoms. *Clonidine* - While clonidine is sometimes used for ADHD, particularly for **hyperactivity** or **tics**, it is not generally considered first-line and can cause **sedation**. - Its mechanism primarily involves stimulating central alpha-2 adrenergic receptors, which can help with impulse control but is distinct from the primary action of atomoxetine. *Dexamphetamine* - This is a **stimulant medication** and is highly effective for ADHD, but it carries a higher potential for **abuse and diversion**, making it less suitable given a family history of substance abuse. - Its mechanism involves increasing dopamine and norepinephrine levels in the brain, which can be reinforcing and contribute to its abuse potential. *Methylphenidate* - Similar to dexamphetamine, methylphenidate is a **stimulant** and a first-line treatment for ADHD, but its potential for **abuse** makes it a less desirable choice in this specific clinical context. - It acts as a norepinephrine-dopamine reuptake inhibitor, increasing the availability of these neurotransmitters, but like other stimulants, its controlled substance status is a concern.

Question 48: Drug capable of causing ocular hypotension with apnea in infants is:-

A. Acetazolamide
B. Latanoprost
C. Apraclonidine
D. Brimonidine (Correct Answer)

Explanation: ***Brimonidine*** - **Brimonidine** is an alpha-2 adrenergic agonist that can cause significant **CNS depression** in infants, leading to **apnea**, lethargy, and bradycardia. - While effective at reducing intraocular pressure, its systemic absorption in infants makes it contraindicated due to severe side effects like respiratory depression. *Acetazolamide* - **Acetazolamide** is a carbonic anhydrase inhibitor that reduces aqueous humor production and is generally safe in infants for glaucoma. - Its main side effects involve metabolic acidosis and electrolyte imbalances, not typically apnea, unless in very high, inappropriate doses. *Latanoprost* - **Latanoprost** is a prostaglandin analog that increases uveoscleral outflow, effectively lowering intraocular pressure. - It is generally safe in infants and its primary ocular side effects include iris pigmentation and eyelash growth, without systemic effects like apnea. *Apraclonidine* - **Apraclonidine** is another alpha-2 adrenergic agonist but with less lipid solubility than brimonidine, resulting in lower CNS penetration. - While it can cause some systemic side effects, its risk of severe apnea in infants is significantly lower compared to brimonidine, but it is still rarely used.

Question 49: A pediatrician was called for attending a new born baby in the labour ward. The serum unconjugated bilirubin of this baby was 33 mg/dL. Which of the following drug taken by mother in late 3rd trimester may have led to this problem?

A. Ampicillin
B. Azithromycin
C. Cotrimoxazole (Correct Answer)
D. Chloroquine

Explanation: ***Cotrimoxazole*** - **Cotrimoxazole** (trimethoprim-sulfamethoxazole) can displace **bilirubin** from albumin-binding sites in the newborn, leading to increased levels of **unconjugated bilirubin** and a higher risk of kernicterus. - Sulfonamides, a component of cotrimoxazole, are known to interfere with **bilirubin metabolism** and transport in neonates, particularly when taken by the mother late in pregnancy. *Ampicillin* - **Ampicillin** is a penicillin-class antibiotic generally considered safe during pregnancy and is not known to cause significant neonatal **hyperbilirubinemia**. - Its mechanism of action does not involve competition for **albumin-binding sites** with bilirubin. *Azithromycin* - **Azithromycin** is a macrolide antibiotic commonly used in pregnancy and does not have a recognized association with significant **unconjugated hyperbilirubinemia** in newborns. - It does not significantly affect the **bilirubin-albumin binding** in neonates. *Chloroquine* - **Chloroquine** is an antimalarial drug, and while generally avoided in the first trimester, it has not been linked to severe neonatal **hyperbilirubinemia** similar to that caused by sulfonamides. - Its primary **side effects** in newborns are not related to bilirubin displacement.

Question 50: Which drug for ADHD has a risk of growth retardation in children?

A. Methylphenidate (Correct Answer)
B. Modafinil
C. Clonidine
D. Atomoxetine

Explanation: ***Methylphenidate*** - **Methylphenidate** (a stimulant) can cause a **transient reduction in growth velocity** due to effects on appetite suppression and potentially growth hormone secretion [1]. - While this reduction is often temporary and catch-up growth typically occurs, it is a **well-documented and clinically significant risk** requiring growth monitoring in children [1, 2]. - Among ADHD medications, stimulants like methylphenidate have the **most pronounced effect on growth** [1].*Modafinil* - **Modafinil** is primarily used for narcolepsy and other sleep disorders, not a first-line treatment for ADHD. - It works through different mechanisms than traditional stimulants and is not typically associated with growth retardation in the ADHD population.*Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist used to treat ADHD, particularly for hyperactivity, impulsivity, and sleep problems. - It does **not have a known risk of growth retardation** in children.*Atomoxetine* - **Atomoxetine** is a non-stimulant medication for ADHD that works by selectively inhibiting norepinephrine reuptake. - While atomoxetine can also affect growth velocity in some children (FDA labeling includes growth monitoring recommendations), the effect is **generally less pronounced than with stimulants like methylphenidate**. - Methylphenidate remains the **most recognized** for this adverse effect among ADHD medications.

Question 51: Which vaccine traditionally required special precautions in children with severe egg allergy?

A. Measles
B. BCG
C. Hepatitis B
D. Influenza (Correct Answer)

Explanation: ***Influenza*** - The influenza vaccine was traditionally produced in **embryonated chicken eggs**, making it a concern for individuals with **severe egg allergies**. - Current guidelines generally state that individuals with egg allergy can receive the flu vaccine, but in the past, special precautions were often recommended. *Measles* - The measles vaccine (MMR) is grown in **chicken embryo fibroblast cultures**, but studies have shown no increased risk of allergic reactions in egg-allergic individuals. - It does not contain significant amounts of **egg protein**, and allergy to eggs is not a contraindication. *BCG* - The BCG vaccine (Bacille Calmette-Guérin) is derived from a strain of *Mycobacterium bovis* and is not produced using **egg components**. - It does not pose a risk for individuals with egg allergy. *Hepatitis B* - The hepatitis B vaccine is a **recombinant vaccine**, meaning it is produced using genetically engineered yeast cells, not **egg components**. - Therefore, it is safe for individuals with egg allergy.

Question 52: A 75-year-old man with chronic kidney disease presents with worsening dyspnea and lower extremity edema. Which class of drugs should be used with caution in this patient?

A. Nonsteroidal anti-inflammatory drugs (NSAIDs) (Correct Answer)
B. Loop diuretics
C. Beta-adrenergic blockers
D. Angiotensin-converting enzyme (ACE) inhibitors

Explanation: ***Nonsteroidal anti-inflammatory drugs (NSAIDs)*** - **NSAIDs should be avoided or used with extreme caution in CKD** as they cause **vasoconstriction of the afferent renal arteriole**, directly reducing **glomerular filtration rate (GFR)** and worsening kidney function - They inhibit **prostaglandin synthesis**, which is critical for maintaining renal blood flow, especially in patients with compromised kidney function who depend on prostaglandins for renal perfusion - In CKD patients, NSAIDs pose **high risk of acute-on-chronic kidney injury**, hyperkalemia, and sodium retention worsening edema - They represent the **highest risk** among the options listed for precipitating acute renal failure *Loop diuretics* - Loop diuretics like **furosemide** are **indicated and beneficial** in patients with volume overload due to heart failure and CKD, effectively reducing dyspnea and edema - While they require monitoring for **electrolyte imbalances** and dose adjustment in CKD, they are a cornerstone of therapy, not a drug to avoid *Beta-adrenergic blockers* - **Beta-blockers** are generally **safe and beneficial** in patients with heart failure and CKD, reducing mortality and improving cardiac function - Some beta-blockers require dose adjustment based on renal function, but they do not directly worsen kidney function *Angiotensin-converting enzyme (ACE) inhibitors* - **ACE inhibitors do require caution in CKD**, particularly during acute illness, volume depletion, or advanced disease, as they can cause **hyperkalemia** and **acute decline in GFR** by dilating the efferent arteriole - However, they differ from NSAIDs in that: (1) their renal effects are **hemodynamic rather than directly nephrotoxic**, (2) they provide **long-term renoprotection** in CKD with proteinuria by reducing intraglomerular pressure, and (3) a **mild, stable rise in creatinine (up to 30%)** is acceptable - While ACE inhibitors require careful monitoring, they are often **beneficial long-term** in CKD, whereas NSAIDs should generally be **avoided entirely**

Question 53: Which antihypertensive medication is contraindicated in pregnancy due to its potential to cause fetal renal damage?

A. Labetalol
B. Nifedipine
C. ACE inhibitors (Correct Answer)
D. Methyldopa

Explanation: ***ACE inhibitors*** - ACE inhibitors are **contraindicated in pregnancy (FDA Category D)** and can cause severe fetal renal damage, including **oligohydramnios**, **renal dysplasia**, and **anuria**, particularly when used in the second and third trimesters. - They inhibit fetal angiotensin II production, which is crucial for normal renal development and function. - **ARBs (Angiotensin Receptor Blockers)** share the same contraindication and risks. *Labetalol* - **Labetalol** is a **beta-blocker** commonly used to manage hypertension in pregnancy and is generally considered safe. - It does not have known associations with fetal renal damage. *Nifedipine* - **Nifedipine**, a **calcium channel blocker**, is another preferred agent for treating hypertension in pregnant women. - It is not contraindicated and is not associated with teratogenic effects on the fetal kidneys. *Methyldopa* - **Methyldopa** is often considered the **first-line antihypertensive** for chronic hypertension in pregnancy due to its long-standing safety record. - It works as a centrally acting alpha-agonist and does not cause fetal renal damage.

Question 54: Which of the following antiepileptic drugs is associated with causing congenital heart disease in the fetus?

A. Carbamazepine
B. Phenytoin
C. Barbiturates
D. Valproate (Correct Answer)

Explanation: ***Valproate*** - **Valproate** is associated with the **highest overall risk of major congenital malformations** among antiepileptic drugs, affecting **10-20%** of exposed fetuses - While **neural tube defects** (spina bifida) are the most characteristic malformation, **cardiac defects** (including atrial septal defects, ventricular septal defects, and coarctation of aorta) occur in approximately **2-3%** of exposed pregnancies - The teratogenic risk is **dose-dependent**, with higher doses (>1000 mg/day) carrying substantially greater risk - Valproate is classified as **FDA Category X** (contraindicated in pregnancy) due to its high teratogenic potential *Phenytoin* - **Phenytoin** is associated with **fetal hydantoin syndrome**, which includes craniofacial abnormalities, limb defects, nail hypoplasia, and growth restriction - Cardiac defects do occur with phenytoin exposure (particularly septal defects), with an estimated risk of **2-3%** - However, the **overall rate of major malformations** is lower than valproate (approximately 6-10%) - While cardiac defects are part of the phenytoin teratogenicity spectrum, valproate carries a higher absolute risk *Carbamazepine* - **Carbamazepine** is primarily associated with **neural tube defects** (0.5-1% risk), particularly spina bifida - The overall risk of major congenital malformations is **approximately 4-6%**, lower than both valproate and phenytoin - Cardiac defects can occur but are less frequently reported compared to other malformations *Barbiturates* - **Barbiturates** (such as phenobarbital) have teratogenic potential including cardiac defects and cleft palate - The overall risk of major malformations is **estimated at 5-7%** - While cardiac defects have been reported, the evidence base is less robust than for valproate, and the absolute risk is lower

Question 55: Which drug causes hypotension with apnea in an infant?

A. Brimonidine (Correct Answer)
B. Dorzolamide
C. Timolol
D. Latanoprost

Explanation: ***Brimonidine*** - **Brimonidine** is an α2-adrenergic agonist that can cross the **blood-brain barrier** in infants, leading to central nervous system depression. - This can cause **apnea**, lethargy, bradycardia, and significant **systemic hypotension** in infants due to their underdeveloped metabolic pathways and greater permeability of the blood-brain barrier. - Brimonidine is **contraindicated in children under 2 years of age** due to these serious adverse effects. *Timolol* - **Timolol** is a non-selective **beta-blocker** that can cause systemic side effects like bradycardia and bronchospasm in infants. - While it can cause respiratory depression, **apnea with hypotension** is less characteristic than with brimonidine-induced CNS depression. *Dorzolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that reduces aqueous humor production. - Systemic absorption can lead to metabolic acidosis, but it is not commonly associated with **apnea and hypotension** in infants compared to **brimonidine**. *Latanoprost* - **Latanoprost** is a **prostaglandin analog** that increases uveoscleral outflow. - It is generally well-tolerated with local side effects like iris color change and eyelash growth, but is **not associated** with systemic effects such as **apnea or hypotension** in infants.

Question 56: A 2-year-old boy weighing 12 kg is diagnosed with vitamin A deficiency. What is the recommended oral dose of vitamin A for him?

A. 200,000 I.U. (Correct Answer)
B. 50,000 I.U.
C. 100,000 I.U.
D. 150,000 I.U.

Explanation: ***200,000 I.U.*** - According to **WHO guidelines**, for children aged **12 months and older** with vitamin A deficiency, the recommended oral dose is **200,000 I.U.** - This dose is given immediately upon diagnosis, repeated the next day, and a third dose is given 2-4 weeks later. - Since this child is **2 years old**, he falls into the ≥12 months category requiring 200,000 I.U. *100,000 I.U.* - A dose of **100,000 I.U.** is recommended for infants aged **6-11 months** with vitamin A deficiency. - This child is 2 years old, making 100,000 I.U. an insufficient dose for his age group. *50,000 I.U.* - A dose of **50,000 I.U.** is recommended for infants **younger than 6 months** diagnosed with vitamin A deficiency. - This dose is too low for a 2-year-old child. *150,000 I.U.* - **150,000 I.U.** is not a standard WHO-recommended dose for vitamin A deficiency treatment in any pediatric age group. - This is an incorrect dosing option.

Question 57: Which drug is primarily used to promote fetal lung maturity?

A. Folic acid
B. Dexamethasone (Correct Answer)
C. Beclomethasone

Explanation: ***Dexamethasone*** - **Dexamethasone** is a synthetic glucocorticoid that rapidly crosses the placenta and stimulates the maturation of fetal lung surfactant production. - It significantly reduces the incidence and severity of **respiratory distress syndrome (RDS)** in preterm infants when administered to the mother. - **Antenatal corticosteroids** (dexamethasone or betamethasone) are given to mothers at risk of preterm delivery between 24-34 weeks of gestation. *Folic acid* - **Folic acid** is a B vitamin crucial for cell growth and DNA synthesis, primarily used to prevent **neural tube defects** in developing fetuses. - It does not have a direct role in promoting fetal lung maturity or surfactant production. *Beclomethasone* - **Beclomethasone** is an inhaled corticosteroid primarily used for the long-term management of **asthma** in children and adults. - While it is a corticosteroid, it is not typically used for systemic administration to the mother to promote fetal lung maturity due to its primary delivery method (inhalation) and limited systemic bioavailability compared to dexamethasone or betamethasone.

Question 58: Which of the following statements about the rotavirus vaccine is true?

A. It is a killed vaccine.
B. It is administered subcutaneously.
C. It is an oral pentavalent vaccine. (Correct Answer)
D. It should be given after 5 years.

Explanation: ***It is an oral pentavalent vaccine.*** - Rotavirus vaccines are **oral vaccines** that provide protection against rotavirus infection, a common cause of **severe diarrhea** in infants and young children. - **RotaTeq** is a **pentavalent live attenuated vaccine** containing five reassortant strains (G1, G2, G3, G4, and P1A) to induce a broad immune response. - **Rotarix** is a monovalent live attenuated vaccine containing one strain (G1P[8]). - Both vaccines are oral and live attenuated, but the statement correctly describes RotaTeq specifically. *It is a killed vaccine.* - The rotavirus vaccines currently in use (both RotaTeq and Rotarix) are **live attenuated vaccines**, not killed vaccines. - Live attenuated vaccines contain weakened versions of the virus that replicate in the host to stimulate an immune response without causing disease. *It is administered subcutaneously.* - The rotavirus vaccine is administered **orally**, typically dropped into the infant's mouth. - This route of administration is preferred for enteric infections like rotavirus, as it can induce **mucosal immunity** in the gastrointestinal tract. *It should be given after 5 years.* - The rotavirus vaccine is recommended for **infants and young children**, with the first dose typically given between **6 and 14 weeks of age**. - Catch-up vaccination is generally not recommended after 8 months of age, and the vaccine is not indicated for children over 5 years.

Question 59: Which drug is linked to hypertrophic pyloric stenosis in infants?

A. Erythromycin (Correct Answer)
B. Ampicillin
C. Rifampicin
D. Tetracycline

Explanation: ***Erythromycin*** - Studies have shown an association between infantile exposure to **erythromycin** and an increased risk of developing **hypertrophic pyloric stenosis**. - This risk is particularly noted when erythromycin is administered during the **first two weeks of life**, possibly due to its potent motilin receptor agonism. *Tetracycline* - **Tetracycline** is known for causing **teeth discoloration** and **bone growth retardation** in infants and children. - It is generally contraindicated in pediatric populations due to these significant side effects, but it is not linked to pyloric stenosis. *Ampicillin* - **Ampicillin** is a penicillin antibiotic commonly used in infants for bacterial infections. - While it can cause side effects like **rashes** and **diarrhea**, there is no established link to hypertrophic pyloric stenosis. *Rifampicin* - **Rifampicin** is an antibiotic primarily used for treating tuberculosis. - Its main side effects include **hepatotoxicity** and **red-orange discoloration of body fluids**, but it has no known association with hypertrophic pyloric stenosis.

Question 60: Which antithyroid drug is preferred during the first trimester of pregnancy due to relatively lower placental transfer?

A. Carbimazole
B. Propylthiouracil (Correct Answer)
C. Both
D. None of the options

Explanation: ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred antithyroid drug during the **first trimester** of pregnancy because it crosses the placenta less readily than methimazole/carbimazole. - While it still crosses the placenta, its lower placental transfer and association with fewer fetal anomalies in early pregnancy make it a safer initial choice, especially to minimize the risk of **fetal embryopathy** associated with methimazole. *Carbimazole* - **Carbimazole** (which is metabolized to methimazole) can cross the placenta more easily than PTU and has been associated with **fetal anomalies**, particularly in the first trimester. - Its use is generally avoided during the first trimester due to concerns about congenital malformations such as **aplasia cutis** and **esophageal atresia**. *Both* - While both drugs can cross the placenta to some extent, their safety profiles and recommended use during pregnancy differ significantly. - Carbimazole (methimazole) has a higher risk of teratogenicity in the first trimester compared to PTU. *None of the options* - This option is incorrect because propylthiouracil is indeed known to cross the placenta and is commonly used in pregnancy, especially during the first trimester. - The choice of antithyroid drug is a critical consideration in managing hyperthyroidism in pregnancy.

Question 61: What is the drug of choice for managing generalized tonic-clonic seizures (GTCS) during pregnancy?

A. Lamotrigine (Correct Answer)
B. CBZ
C. Levetiracetam
D. Valproate

Explanation: ***Lamotrigine*** - **Lamotrigine** is considered **one of the preferred drugs** for managing epilepsy during pregnancy due to its relatively **low teratogenic risk** compared to older antiepileptic drugs. - Its established safety profile in pregnancy makes it a preferred option to balance seizure control and **fetal well-being**. - **Important Note:** For **GTCS specifically**, lamotrigine and levetiracetam are both considered appropriate first-line choices, with selection depending on individual patient factors and seizure control history. - Lamotrigine levels **decrease during pregnancy** and require monitoring and dose adjustments. *CBZ* - **Carbamazepine (CBZ)** is associated with an increased risk of **neural tube defects** and other congenital malformations when used during pregnancy, making it less favorable. - While effective for GTCS, its teratogenicity often leads to avoidance or careful consideration of alternatives in pregnant women. *Levetiracetam* - **Levetiracetam** is increasingly recognized as an **excellent choice for GTCS in pregnancy** with a favorable safety profile and growing evidence base. - Many recent guidelines and clinical practices favor levetiracetam as **first-line for GTCS** due to its low risk of major congenital malformations and good efficacy. - It is a **medically appropriate alternative** to lamotrigine, and in some contexts may be preferred, particularly for primary generalized epilepsy. *Valproate* - **Valproate** has the highest risk of **teratogenicity** among common antiepileptic drugs, including a significant risk of **neural tube defects**, developmental delay, autism spectrum disorder, and other anomalies. - Due to these significant risks, valproate is generally **contraindicated** in women of childbearing potential, especially during pregnancy, unless no other effective and safer alternative exists.

Question 62: What is the initial loading dose of chloroquine base for treating uncomplicated malaria in children?

A. 5 mg/kg
B. 10 mg/kg (maximum 600 mg) (Correct Answer)
C. 15 mg/kg
D. 25 mg/kg

Explanation: ***10 mg/kg (maximum 600 mg)*** - The standard **initial loading dose** of chloroquine base for uncomplicated malaria in children is **10 mg/kg body weight**, with a maximum cap of **600 mg** to prevent toxicity. - This is followed by **5 mg/kg** at 6 hours, 24 hours, and 48 hours (total course of 25 mg/kg over 3 days). - This represents **WHO-recommended** weight-based dosing for pediatric malaria treatment. *5 mg/kg* - **5 mg/kg** is the dose for the **subsequent doses** (at 6, 24, and 48 hours after the initial dose), not the initial loading dose. - The initial dose must be higher (10 mg/kg) to rapidly achieve therapeutic blood levels. *15 mg/kg* - **15 mg/kg** exceeds the recommended initial dose and increases the risk of **chloroquine toxicity**. - Chloroquine has a narrow therapeutic index, and overdosing can cause serious **cardiovascular** (arrhythmias, hypotension) and **neurological** effects (seizures, visual disturbances). *25 mg/kg* - **25 mg/kg** represents the **total cumulative dose** over the entire 3-day treatment course, not the initial single dose. - Giving this amount as a single dose would result in severe toxicity and is contraindicated.

Question 63: What is the recommended dose of oseltamivir for a child aged 9 months?

A. 2 mg/kg twice daily for 5 days
B. 2.5 mg/kg twice daily for 5 days
C. 3 mg/kg twice daily for 5 days (Correct Answer)
D. 3.5 mg/kg twice daily for 5 days

Explanation: ***3 mg/kg twice daily for 5 days*** - For children aged **less than 1 year**, and weighing less than 15 kg, the recommended oseltamivir dose is **3 mg/kg** administered **twice daily** for 5 days. - This dosage regimen is effective in treating influenza and is based on studies of its **pharmacokinetics** and **efficacy** in this age group. *2 mg/kg twice daily for 5 days* - This dosage is **lower than recommended** for children under 1 year of age and may not achieve adequate therapeutic drug levels. - Subtherapeutic dosing could lead to **reduced antiviral efficacy** and potentially poorer clinical outcomes. *2.5 mg/kg twice daily for 5 days* - Similar to the 2 mg/kg dose, this is **below the standard recommendation** for infants and young children in this age bracket. - Inadequate dosing increases the risk of **treatment failure** and the development of **antiviral resistance**. *3.5 mg/kg twice daily for 5 days* - This dosage might be considered **higher than necessary** for a 9-month-old child and could potentially increase the risk of **adverse effects**. - While exact toxicities are rare within a reasonable range, adherence to recommended guidelines optimizes the **benefit-risk profile**.

Question 64: What is the drug of choice for hypertension in pregnancy?

A. Verapamil
B. Methyldopa (Correct Answer)
C. Furosemide
D. Enalapril

Explanation: ***Methyldopa*** - **Methyldopa** is considered a first-line agent because of its established safety profile for both the mother and the fetus throughout pregnancy. - It acts centrally as an **alpha-2 adrenergic agonist**, reducing sympathetic outflow and thereby lowering blood pressure. *Enalapril* - **Angiotensin-converting enzyme (ACE) inhibitors** like Enalapril are contraindicated in pregnancy due to their association with **fetal renal abnormalities**, **oligohydramnios**, and **growth restriction**, especially in the second and third trimesters. - Their use can lead to **fetal hypotension** and potentially **fetal death**. *Verapamil* - **Calcium channel blockers** like Verapamil are generally considered second-line agents for hypertension in pregnancy. - While generally safer than ACE inhibitors, **Labetalol** and **Nifedipine** are often preferred among calcium channel blockers, and **Methyldopa** has a longer track record of safety. *Furosemide* - **Diuretics** like Furosemide are generally not recommended for chronic hypertension in pregnancy as they can **reduce plasma volume** and potentially impair placental perfusion. - They are primarily used in cases of **pulmonary edema** or severe fluid overload, rather than routine management of hypertension.

Question 65: One of the following antihypertensives is not used in pregnancy:

A. Hydralazine
B. Enalapril (Correct Answer)
C. Methyldopa
D. Nifedipine

Explanation: ***Enalapril*** - **Angiotensin-converting enzyme (ACE) inhibitors** like enalapril are teratogenic and contraindicated in pregnancy. - They can cause **renal dysfunction, oligohydramnios, fetal growth restriction**, and even **fetal death** when used during the second and third trimesters. *Methyldopa* - **Methyldopa** is considered a first-line antihypertensive in pregnancy due to its long-standing safety record. - It acts as a **central alpha-2 adrenergic agonist**, reducing sympathetic outflow. *Hydralazine* - **Hydralazine** is a direct-acting vasodilator often used as a second-line agent or in hypertensive emergencies during pregnancy. - It effectively reduces **peripheral vascular resistance** and is considered safe for both mother and fetus. *Nifedipine* - **Nifedipine**, a calcium channel blocker, is a common and safe choice for managing hypertension in pregnancy, particularly for chronic hypertension or preeclampsia. - It causes **vasodilation** by relaxing vascular smooth muscle.

Question 66: Which of the following drugs is given during pregnancy, resulting in fetal abnormalities such as cleft lip and central nervous system defects?

A. Warfarin
B. Phenytoin
C. Valproic acid
D. Retinoic acid (Vitamin A derivative) (Correct Answer)

Explanation: ***Retinoic acid (Vitamin A derivative)*** - **Retinoic acid** (including isotretinoin) is a **potent teratogen** with a characteristic pattern of malformations including **craniofacial defects (cleft lip/palate)**, **cardiac abnormalities** (transposition of great arteries, VSD), and **severe CNS defects** (hydrocephalus, microcephaly, neural tube defects) - The mechanism involves **disruption of gene expression** during embryogenesis, particularly affecting **neural crest cell migration** critical for facial and cardiac development - The combination of **cleft lip + CNS defects** is characteristic of retinoic acid embryopathy, making it the most fitting answer *Phenytoin* - **Phenytoin** causes **fetal hydantoin syndrome** with craniofacial anomalies (cleft lip/palate in ~5-10% of cases), **hypoplastic nails and distal phalanges**, wide-set eyes, and mild developmental delays - While cleft lip can occur, the overall pattern emphasizes **digital/nail hypoplasia** and milder CNS effects compared to retinoic acid *Valproic acid* - **Valproic acid** is primarily associated with **neural tube defects** (spina bifida in 1-2% of exposures), the hallmark of valproate embryopathy - Can cause minor facial anomalies and cardiac defects, but the **characteristic feature is spina bifida**, not cleft lip *Warfarin* - **Warfarin** causes **fetal warfarin syndrome** with distinctive features: **nasal hypoplasia**, **stippled epiphyses** (chondrodysplasia punctata), and potential CNS defects from hemorrhage - Does **not** typically cause cleft lip; the skeletal abnormalities are the defining feature

Question 67: Which of the following drugs can cause cartilage damage in children?

A. Cotrimoxazole and other sulfonamides
B. Penicillin and other beta-lactams
C. Metronidazole and other nitroimidazoles
D. Ciprofloxacin and other fluoroquinolones (Correct Answer)

Explanation: ***Ciprofloxacin and other fluoroquinolones*** - Fluoroquinolones, including ciprofloxacin, are known to cause **arthropathy** (joint disease) and **cartilage damage** in growing children and adolescents [1]. - This adverse effect has limited their use in pediatric populations, typically reserved for severe infections where other effective and safer alternatives are unavailable [1]. *Cotrimoxazole and other sulfonamides* - Sulfonamides are primarily associated with adverse effects like **hypersensitivity reactions** (e.g., Stevens-Johnson syndrome), **bone marrow suppression**, and **crystalluria**. - They are not typically linked to cartilage damage in children. *Penicillin and other beta-lactams* - Penicillins and other beta-lactam antibiotics are generally considered **safe in children** and are a common choice for pediatric infections. - Their primary adverse effects are hypersensitivity reactions, such as **rashes** or **anaphylaxis**, and gastrointestinal disturbances, not cartilage damage. *Metronidazole and other nitroimidazoles* - Metronidazole's main adverse effects include **gastrointestinal upset**, **metallic taste**, and **neurological symptoms** (e.g., peripheral neuropathy, seizures with high doses). - There is no known association between metronidazole and cartilage damage in children.

Question 68: Which drug is considered safest for treating latent tuberculosis in pregnancy?

A. INH (Correct Answer)
B. Rifampicin
C. Ethambutol
D. Streptomycin

Explanation: ***INH (Isoniazid)*** - **Isoniazid (INH)** is considered the **safest and preferred agent** for treating **latent tuberculosis infection (LTBI)** in pregnant women. - It can be given as a **6-9 month daily regimen** with **pyridoxine (vitamin B6)** supplementation to prevent maternal and fetal **peripheral neuropathy**. - Well-studied with extensive safety data in pregnancy (FDA Category A/C depending on source, but generally considered safe). *Rifampicin* - While generally safe in pregnancy for **active TB**, its use for **LTBI** is often deferred or avoided, particularly in the first trimester, due to theoretical concerns. - **Rifampicin** can interact with other medications through hepatic enzyme induction, which might be a consideration for pregnant women on multiple therapies. - Not the first-line choice for LTBI monotherapy in pregnancy. *Ethambutol* - **Ethambutol** is primarily used in **multi-drug regimens** for **active tuberculosis** and is less commonly used alone for **LTBI**. - Although generally considered safe in pregnancy, **INH** remains the preferred monotherapy for LTBI treatment due to more extensive safety data. *Streptomycin* - **Streptomycin** is **contraindicated during pregnancy** due to significant risk of **ototoxicity** (damage to cranial nerve VIII) in the fetus, leading to **permanent congenital deafness**. - It is an **aminoglycoside antibiotic** and should be avoided in pregnant women unless absolutely necessary for life-threatening conditions with no other alternatives.

Question 69: Which antimalarial drug is considered the safest during pregnancy?

A. Chloroquine (Correct Answer)
B. Pyrimethamine
C. None of the options
D. Proguanil

Explanation: ***Chloroquine*** - **Chloroquine** is considered the **safest antimalarial drug during pregnancy** and is the drug of choice for malaria prophylaxis and treatment in pregnant women. - It has been used extensively for decades with an **excellent safety profile** across all trimesters, including the first trimester. - Classified as **FDA Pregnancy Category C**, chloroquine has extensive clinical data supporting its safety, with no significant teratogenic effects reported. - **WHO and CDC** both recommend chloroquine as the preferred antimalarial for pregnant women in chloroquine-sensitive malaria areas. - It is effective against **Plasmodium vivax** and chloroquine-sensitive **P. falciparum** strains. *Pyrimethamine* - **Pyrimethamine** is a **dihydrofolate reductase inhibitor** that interferes with folate metabolism, which is crucial during pregnancy for fetal neural tube development. - Should be used with **caution in the first trimester** due to risk of **folate deficiency** and potential teratogenicity. - When used (typically as sulfadoxine-pyrimethamine), it must be co-administered with **folic acid supplementation** to reduce risks. - Not considered first-line due to these concerns. *Proguanil* - **Proguanil** is relatively safe but is typically used in **combination therapy** (atovaquone-proguanil) rather than as monotherapy. - While it has a reasonable safety profile as a **dihydrofolate reductase inhibitor**, it has **less extensive safety data** during pregnancy compared to chloroquine. - Generally considered a **second-line option** when chloroquine-resistant malaria is present. - Often requires folate supplementation when used during pregnancy. *None of the options* - This is incorrect because **chloroquine** is definitively recognized as the safest antimalarial during pregnancy, with decades of safe use and endorsement by major health organizations including WHO and CDC.

Question 70: What are the side effects of diethylstilbestrol when used in a pregnant woman?

A. Deep vein thrombosis in pregnant woman
B. Feminization of external genitalia of male offspring
C. Virilization of the external genitalia of female offspring
D. Infertility and development of vaginal carcinoma in female offspring (Correct Answer)

Explanation: ***Infertility and development of vaginal carcinoma in female offspring*** - Exposure to **diethylstilbestrol (DES)** *in utero* significantly increases the risk of developing **clear cell adenocarcinoma of the vagina** and **cervix** in female offspring. - Female offspring may also experience **structural abnormalities** of the reproductive tract and **infertility** due to DES exposure. *Deep vein thrombosis in pregnant woman* - While estrogens can increase the risk of **thromboembolic events**, the primary and well-documented long-term adverse effects of *in-utero* DES exposure relate specifically to the offspring's reproductive health, not acute maternal DVT. - DES was prescribed to prevent miscarriage, and its risks to the fetus were not fully understood at the time of its widespread use. *Feminization of external genitalia of male offspring* - **Diethylstilbestrol** is an **estrogen** and would not cause feminization of male genitalia; rather, *in-utero* exposure in males has been linked to an increased risk of **epididymal cysts**, **cryptorchidism**, and **hypogonadism**. - Feminization of male external genitalia is typically associated with **androgen deficiency** or **excess estrogen** from other sources or genetic conditions affecting sex differentiation. *Virilization of the external genitalia of female offspring* - **Virilization** in female offspring is caused by exposure to **excess androgens** *in utero*, as seen in conditions like **congenital adrenal hyperplasia** or maternal androgen-producing tumors. - **Diethylstilbestrol** is an estrogen and would not cause virilization; instead, it can lead to anatomical abnormalities of the female reproductive tract without masculinizing effects.

Question 71: All the following antihypertensive drugs are used in pregnancy except for one. Which one is contraindicated?

A. Nifedipine
B. Labetalol
C. Methyldopa
D. Enalapril (Correct Answer)

Explanation: ***Enalapril*** - **ACE inhibitors** like enalapril are absolutely contraindicated in pregnancy due to their association with **fetal renal dysfunction**, oligohydramnios, and **fetal death**. - They should be avoided throughout all trimesters, especially during the **second and third trimesters**. *Nifedipine* - **Nifedipine**, a calcium channel blocker, is considered a safe and effective antihypertensive agent during pregnancy. - It rapidly reduces blood pressure and is often used for acute management of **severe hypertension** in pregnancy, including pre-eclampsia. *Labetalol* - **Labetalol** is a combined alpha and beta-blocker that is a first-line treatment for hypertension in pregnancy. - It has a good safety profile for both the mother and the fetus, with extensive clinical experience supporting its use. *Methyldopa* - **Methyldopa** is one of the oldest and most studied antihypertensive drugs in pregnancy and is generally considered a first-line agent. - It acts centrally as an alpha-2 adrenergic agonist, reducing sympathetic outflow, and has shown good safety outcomes for long-term use.

Question 72: Which of the following is a safe drug for a nursing mother?

A. Chloramphenicol
B. Lithium
C. Amphetamines
D. Digoxin (Correct Answer)

Explanation: ***Digoxin*** - **Digoxin** is considered generally safe during lactation because it has a **low milk-to-plasma ratio** and is poorly absorbed orally by the infant. - The amount of digoxin transferred into breast milk is minimal and unlikely to cause clinically significant effects in the infant. *Chloramphenicol* - **Chloramphenicol** can cause severe adverse effects in infants, including **bone marrow suppression** and the **gray baby syndrome**, due to its ability to cross into breast milk. - Its use is contraindicated in nursing mothers due to these serious risks. *Lithium* - **Lithium** is excreted into breast milk and can reach therapeutic levels in the infant, potentially causing **lethargy**, **hypotonia**, **cyanosis**, and **cardiovascular adverse effects**. - Monitoring infant serum lithium levels is crucial if used, but it's generally advised against due to safety concerns. *Amphetamines* - **Amphetamines** are secreted into breast milk and can cause **irritability**, **poor feeding**, **sleep disturbances**, and even **seizures** in nursing infants. - Due to the high risk of central nervous system stimulation and other adverse effects, amphetamines are generally considered contraindicated during breastfeeding.

Question 73: A pregnant lady in the third trimester is visiting a chloroquine-resistant malaria endemic area. Which drug is considered safe for her in terms of malaria prophylaxis?

A. Doxycycline
B. Atovaquone/Proguanil
C. Primaquine
D. Mefloquine (Correct Answer)

Explanation: ***Mefloquine*** - **Mefloquine** is generally considered safe for malaria prophylaxis in pregnant women, especially during the second and third trimesters. - It is an effective drug against **chloroquine-resistant malaria** and has good tolerability in this population. *Doxycycline* - **Doxycycline** is contraindicated in pregnancy, particularly during the second and third trimesters, due to its potential to cause **fetal skeletal and dental abnormalities**. - It can lead to permanent tooth discoloration and inhibit bone growth in the fetus. *Atovaquone/Proguanil* - **Atovaquone/Proguanil** is generally not recommended for malaria prophylaxis during pregnancy due to **limited safety data**. - While animal studies have not shown significant teratogenicity, its use is usually reserved for situations where other safer options are unavailable or unsuitable. *Primaquine* - **Primaquine** is contraindicated in pregnancy because it can cause **hemolytic anemia** in the fetus if the fetus has **glucose-6-phosphate dehydrogenase (G6PD) deficiency**. - Its use is specifically avoided in pregnancy to prevent this risk.

Question 74: Which of the following anticoagulants is the preferred choice for safe use in pregnancy?

A. Warfarin
B. Low molecular weight heparin (LMWH) (Correct Answer)
C. Unfractionated heparin (UFH)
D. Direct oral anticoagulants (DOACs)

Explanation: ***Low molecular weight heparin (LMWH)*** - **LMWH** does not cross the **placenta** and is the **preferred anticoagulant** for use throughout all trimesters of pregnancy. - It has a predictable anticoagulant response with **once or twice daily dosing** and does not require routine monitoring. - **Lower risk** of **heparin-induced thrombocytopenia (HIT)** and **osteoporosis** compared to unfractionated heparin. - **Longer half-life** allows for more convenient dosing and better patient compliance. *Warfarin* - **Warfarin** is a **teratogen** that crosses the placenta and can cause **fetal warfarin syndrome**, characterized by nasal hypoplasia, stippled epiphyses, and central nervous system abnormalities, particularly when used in the **first trimester** (6-12 weeks). - It also carries a high risk of **fetal bleeding**, especially in late pregnancy and during delivery. - **Contraindicated** in pregnancy except in very specific circumstances (e.g., mechanical heart valves where benefits may outweigh risks). *Unfractionated heparin (UFH)* - While **UFH** also does not cross the placenta and is considered **safe in pregnancy**, it is **less preferred** than LMWH. - Requires **frequent monitoring** of **activated partial thromboplastin time (aPTT)** due to unpredictable pharmacokinetics and variable bioavailability. - Long-term use associated with **higher risk** of **osteoporosis** and **heparin-induced thrombocytopenia (HIT)** compared to LMWH. - May be preferred over LMWH in specific situations: peripartum period (shorter half-life for easier reversal), severe renal impairment, or when immediate reversal with protamine may be needed. *Direct oral anticoagulants (DOACs)* - **DOACs** (rivaroxaban, apixaban, dabigatran, edoxaban) are **contraindicated** in pregnancy due to insufficient safety data. - Animal studies suggest potential for placental crossing and **teratogenic effects**. - Lack of reversal agents and concerns about **fetal bleeding** make them unsuitable for use in pregnancy.

Question 75: A newborn was given a drug in the neonatal ICU, but then was found in respiratory distress. The likely drug is?

A. Morphine (Correct Answer)
B. Naloxone
C. Salbutamol
D. Sodium bicarbonate

Explanation: ***Morphine*** - **Morphine** is an opioid that can cause **respiratory depression** as a significant side effect, especially in neonates who have immature metabolic pathways. - Neonates have a reduced capacity to metabolize and excrete opioids, leading to prolonged effects and a higher risk of **respiratory distress**. *Naloxone* - **Naloxone** is an opioid antagonist used to **reverse opioid overdose** and respiratory depression. - Administering naloxone would improve, not worsen, respiratory distress if it were opioid-induced. *Salbutamol* - **Salbutamol** is a beta-agonist used to **dilate airways** and treat bronchospasm, which would typically improve breathing. - It is not known to cause respiratory distress; rather, it's used to alleviate it in conditions like asthma or bronchiolitis. *Sodium bicarbonate* - **Sodium bicarbonate** is used to treat **metabolic acidosis**, which can sometimes be associated with respiratory issues but does not directly cause respiratory distress itself. - Its primary action is to buffer excess acid in the blood, and while it might impact respiratory drive indirectly, it is not a direct cause of respiratory depression.

Question 76: The drug of choice for hyperthyroidism during the 2nd trimester of pregnancy is:

A. Propylthiouracil
B. Carbimazole (Correct Answer)
C. Sodium iodide
D. Radioactive iodine

Explanation: ***Carbimazole*** - **Carbimazole** is converted to **methimazole** in the body, which is generally preferred in the second and third trimesters due to a lower risk of serious liver toxicity compared to propylthiouracil. - While propylthiouracil is preferred in the first trimester, **methimazole/carbimazole** is considered safer in later trimesters after the period of major organogenesis. *Propylthiouracil* - **Propylthiouracil (PTU)** is the drug of choice for hyperthyroidism during the **first trimester** of pregnancy because of a lower risk of teratogenicity compared to methimazole/carbimazole. - However, **PTU** carries a risk of **hepatic toxicity** in the mother, making carbimazole/methimazole preferable in the second and third trimesters once the initial teratogenic risk largely passes. *Sodium iodide* - **Sodium iodide** is generally **contraindicated** in pregnancy for routine treatment of hyperthyroidism as it can cross the placenta and potentially cause **fetal goiter** and **hypothyroidism**. - Its use is typically limited to **thyroid storm** or preparation for thyroidectomy when other options are not suitable. *Radioactive iodine* - **Radioactive iodine (I-131)** is **absolutely contraindicated** during any trimester of pregnancy and lactation. - It rapidly crosses the placenta and can **ablate the fetal thyroid gland**, leading to permanent fetal hypothyroidism.

Question 77: Which one of the following drugs is used for fetal therapy in congenital adrenal hyperplasia?

A. Hydrocortisone
B. Prednisolone
C. Fludrocortisone
D. Dexamethasone (Correct Answer)

Explanation: ***Dexamethasone*** - Administered to the mother, **dexamethasone** crosses the placenta and suppresses the fetal adrenal gland's excessive androgen production in **congenital adrenal hyperplasia (CAH)**. - This therapy aims to prevent or reduce the **virilization of female fetuses** when CAH is suspected based on genetic screening of the parents. *Hydrocortisone* - **Hydrocortisone** is a glucocorticoid used for replacement therapy in children and adults with CAH, but it is not typically used for prenatal fetal therapy. - Its shorter half-life and mineralocorticoid activity make it less suitable for transplacental suppression compared to dexamethasone. *Prednisolone* - While prednisolone is a glucocorticoid, it is poorly metabolized by the placenta and does not effectively cross into the fetal circulation to reach therapeutic concentrations. - Therefore, it is not an effective drug for directly treating the fetus in utero. *Fludrocortisone* - **Fludrocortisone** is a mineralocorticoid used in CAH to prevent **salt-wasting crises** by promoting sodium retention, but it does not suppress androgen production. - It is part of postnatal treatment for CAH, not a prenatal fetal therapy to prevent virilization.

Question 78: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?

A. decreased renal excretion of drugs
B. decreased hepatic metabolism
C. decreased volume of distribution (Correct Answer)
D. increased receptor sensitivity

Explanation: ***decreased volume of distribution*** - A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**. - However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs. *decreased renal excretion of drugs* - **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance. - This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**. *decreased hepatic metabolism* - Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age. - This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations. *increased receptor sensitivity* - Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs. - This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.

Question 79: A 75-year-old man with chronic kidney disease presents with worsening dyspnea and lower extremity edema. Which class of drugs should be used cautiously in this patient?

A. NSAIDs (Correct Answer)
B. Beta-blockers
C. Diuretics
D. ACE inhibitors

Explanation: ***NSAIDs*** - **NSAIDs** can cause **acute kidney injury** by inhibiting prostaglandin synthesis, which leads to **afferent arteriolar vasoconstriction** and reduced renal blood flow. This effect is exaggerated in patients with **pre-existing chronic kidney disease**. - They also can exacerbate **fluid retention** and worsen **edema** and symptoms of **heart failure**, which is particularly problematic in a patient with dyspnea and lower extremity edema. *ACE inhibitors* - While generally beneficial in CKD to slow progression, **ACE inhibitors** can cause **acute kidney injury** in patients with **renal artery stenosis** or severe volume depletion due to efferent arteriolar vasodilation. - They can also lead to **hyperkalemia**, which requires monitoring, but they are not contraindicated in this patient's presentation per se. *Beta-blockers* - **Beta-blockers** are often prescribed for cardiovascular conditions common in CKD patients, such as **hypertension** and **heart failure**, and are generally safe in CKD with appropriate dosing. - While some beta-blockers are renally excreted, their primary mechanism does not directly worsen kidney function or fluid retention in the same way NSAIDs do. *Diuretics* - **Diuretics** are essential in managing fluid overload, dyspnea, and edema in patients with **chronic kidney disease** and heart failure. - Although loop diuretics may be less effective with reduced kidney function and higher doses might be needed, they are not typically used cautiously; rather, they are a cornerstone of treatment for these symptoms.

Practice by Chapter

Developmental Pharmacology

Practice Questions

Pediatric Dosing Principles

Practice Questions

Neonatal Pharmacology

Practice Questions

Pharmacotherapy in Children

Practice Questions

Age-Related Changes in Pharmacokinetics

Practice Questions

Age-Related Changes in Pharmacodynamics

Practice Questions

Polypharmacy in the Elderly

Practice Questions

Medication Adherence in Elderly

Practice Questions

Inappropriate Prescribing in Elderly

Practice Questions

Deprescribing Principles

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free